立直し-地上天国

https://apps.who.int/gb/inb/pdf_files/inb7/A_INB7_3-en.pdf

SEVENTH MEETING OF THE INTERGOVERNMENTAL
NEGOTIATING BODY TO DRAFT AND NEGOTIATE
A WHO CONVENTION, AGREEMENT OR OTHER
INTERNATIONAL INSTRUMENT ON PANDEMIC
PREVENTION, PREPAREDNESS AND RESPONSE A/INB/7/3
Provisional agenda item 2 30 October 2023
Proposal for negotiating text
of the WHO Pandemic Agreement
A/INB/7/3
2
Contents
Chapter I. Introduction …………………………………………………………………………………………………………………… 5
Article 1. Use of terms …………………………………………………………………………………………………………… 5
Article 2. Objective and scope ………………………………………………………………………………………………… 6
Article 3. General principles and approaches…………………………………………………………………………….. 7
Chapter II. The world together equitably: Achieving equity in, for and through pandemic prevention,
preparedness and response ……………………………………………………………………………………….. 8
Article 4. Pandemic prevention and public health surveillance ……………………………………………………. 8
Article 5. One Health …………………………………………………………………………………………………………….. 9
Article 6. Preparedness, readiness and resilience ……………………………………………………………………… 10
Article 7. Health and care workforce ……………………………………………………………………………………… 11
Article 8. Preparedness monitoring and functional reviews……………………………………………………….. 12
Article 9. Research and development……………………………………………………………………………………… 12
Article 10. Sustainable production …………………………………………………………………………………………… 14
Article 11. Transfer of technology and know-how …………………………………………………………………….. 15
Article 12. Access and benefit-sharing …………………………………………………………………………………….. 16
Article 13. Global Supply Chain and Logistics………………………………………………………………………….. 18
Article 14. Regulatory strengthening ……………………………………………………………………………………….. 20
Article 15. Compensation and liability management ………………………………………………………………….. 20
Article 16. International collaboration and cooperation………………………………………………………………. 21
Article 17. Whole-of-government and whole-of-society approaches at the national level ……………….. 21
Article 18. Communication and public awareness ……………………………………………………………………… 22
Article 19. Implementation capacities and support …………………………………………………………………….. 22
Article 20. Financing …………………………………………………………………………………………………………….. 23
Chapter III. Institutional arrangements and final provisions ………………………………………………………………. 24
Article 21. Conference of the Parties ……………………………………………………………………………………….. 24
Article 22. Right to vote…………………………………………………………………………………………………………. 26
Article 23. Reports to the Conference of the Parties …………………………………………………………………… 26
Article 24. Secretariat ……………………………………………………………………………………………………………. 26
Article 25. Relationship with other international agreements and instruments ……………………………….. 27
Article 26. Reservations …………………………………………………………………………………………………………. 27
Article 27. Withdrawal…………………………………………………………………………………………………………… 27
Article 28. Amendments ………………………………………………………………………………………………………… 28
Article 29. Annexes ………………………………………………………………………………………………………………. 28
Article 30. Protocols ……………………………………………………………………………………………………………… 28
Article 31. Signature ……………………………………………………………………………………………………………… 29
Article 32. Ratification, acceptance, approval, formal confirmation or accession …………………………… 29
A/INB/7/3
3
Article 33. Entry into force …………………………………………………………………………………………………….. 30
Article 34. Settlement of disputes ……………………………………………………………………………………………. 30
Article 35. Depositary……………………………………………………………………………………………………………. 30
Article 36. Authentic texts ……………………………………………………………………………………………………… 30
A/INB/7/3
4
The Parties to the WHO Pandemic Agreement,
1. Recognizing that the World Health Organization is fundamental to strengthening pandemic
prevention, preparedness and response, as it is the directing and coordinating authority on international
health work,
2. Recalling the Constitution of the World Health Organization, which states that the enjoyment of
the highest attainable standard of health is one of the fundamental rights of every human being without
distinction of race, religion, political belief, economic or social condition,
3. Recognizing that the international spread of disease is a global threat with serious consequences
for lives, livelihoods, societies and economies that calls for the widest possible international cooperation
in an effective, coordinated, appropriate and comprehensive international response, while reaffirming
the principle of sovereignty of States Parties in addressing public health matters,
4. Noting with concern that the coronavirus disease (COVID-19) pandemic revealed serious
shortcomings in preparedness at national and global levels for the timely and effective prevention and
detection of, and response to, health emergencies,
5. Deeply concerned by the gross inequities at national and international levels that hindered timely
and equitable access to medical and other COVID-19 pandemic-related products, notably vaccines,
oxygen supplies, personal protective equipment, diagnostics and therapeutics,
6. Recognizing the critical role of whole-of-government and whole-of-society approaches at country
and community levels, and the importance of international, regional and cross-regional collaboration,
coordination and global solidarity in achieving sustainable improvements in pandemic prevention,
preparedness and response,
7. Recognizing the importance of ensuring political commitment, resourcing and attention across
sectors for pandemic prevention, preparedness and response,
8. Reaffirming the importance of multisectoral collaboration at national, regional and international
levels to: safeguard human health; detect and prevent health threats at the animal and human interface,
zoonotic spill-over and mutations; and sustainably balance and optimize the health of people, animals
and ecosystems in a One Health approach,
9. Reiterating the need to work towards building and strengthening resilient health systems, with
skilled and trained health and care workers, to advance universal health coverage and to adopt an
equitable approach to mitigate the risk that pandemics exacerbate existing inequities in access to health
services,
10. Recognizing that the protection of intellectual property rights is important for the development of
new medical products, and recalling that intellectual property rights do not, and should not, prevent
Member States from taking measures to protect public health, and further recognizing concerns about
the effects of intellectual property rights on prices,
11. Underscoring the importance of promoting the early, safe, transparent and rapid sharing of
samples and genetic sequence data of pathogens with pandemic potential, as well as the fair and
equitable sharing of benefits arising therefrom, taking into account relevant national and international
laws, regulations, obligations and frameworks, including the International Health Regulations, the
A/INB/7/3
5
Convention on Biological Diversity and the Nagoya Protocol on Access to Genetic Resources and the
Fair and Equitable Sharing of Benefits Arising from their Utilization, and the Pandemic Influenza
Preparedness Framework, and also mindful of the work being undertaken in other relevant areas and by
other United Nations entities and multilateral organizations or agencies,
12. Acknowledging that pandemic prevention, preparedness and response at all levels and in all
sectors, particularly in developing countries, require predictable, sustainable and sufficient financial,
human, logistic and technical resources, and that unequal development across countries in the promotion
of health and control of disease, especially communicable disease, is a common danger that requires
support through international collaboration,
13. Noting the adoption of the Political Declaration of the United Nations General Assembly
High-level Meeting on Pandemic Prevention, Preparedness and Response, during the 78th session of the
United Nations General Assembly, which affirms the need to prioritize equity and respect for human
rights and strengthen pandemic prevention, preparedness and response capacities,
Have agreed as follows:
Chapter I. Introduction
Article 1. Use of terms
For the purposes of the WHO Pandemic Agreement:
(a) “genetic sequences” means the order of nucleotides identified in a molecule of DNA or
RNA. They contain the genetic information that determines the biological characteristics of an
organism or a virus;
(b) “genomics” means the study of the total or part of the genetic or epigenetic sequence
information of organisms and attempts to understand the structure and function of these sequences
and downstream biological products. Genomics in health examines molecular mechanisms and
the interplay of this molecular information, health interventions and environmental factors in
disease;
(c) “infodemic” means too much information, false or misleading information, in digital and
physical environments during a disease outbreak. It causes confusion and risk-taking behaviours
that can harm health. It also leads to mistrust in health authorities and undermines public health
and social measures;
(d) “One Health approach” means an integrated, unifying approach that aims to sustainably
balance and optimize the health of people, animals and ecosystems. It recognizes that the health
of humans, domestic and wild animals, plants and the wider environment (including ecosystems)
is closely linked and interdependent. The approach mobilizes multiple sectors, disciplines and
communities at varying levels of society to work together to foster well-being and tackle threats
to health and ecosystems, while addressing the collective need for clean water, energy and air,
safe and nutritious food, taking action on climate change, and contributing to sustainable
development;
(e) “pandemic” means the global spread of a pathogen or variant that infects human
populations with limited or no immunity through sustained and high transmissibility from person
to person, overwhelming health systems with severe morbidity and high mortality and causing
A/INB/7/3
6
social and economic disruptions, all of which requires effective national and global collaboration
and coordination for its control;
(f) “pandemic-related products” means products that are needed for pandemic prevention,
preparedness and response, which may include, without limitation, diagnostics, therapeutics,
medicines, vaccines, personal protective equipment, syringes and oxygen;
(g) “Party” means a State or regional economic integration organization that has consented to
be bound by this Agreement, in accordance with its terms, and for which this Agreement is in
force;
(h) “pathogen with pandemic potential” means any pathogen that has been identified to infect
humans and that is potentially highly transmissible, capable of wide, uncontrollable spread in
human populations, and highly virulent, making it likely to cause significant morbidity and/or
mortality in humans;
(i) “persons in vulnerable situations” means individuals, groups or communities with a
disproportionate increased risk of infection, severity, disease or mortality in the context of a
pandemic, including vulnerability due to discrimination on the basis of race, colour, sex,
language, religion, political or other opinion, national or social origin, property, birth or other
status;
(j) “recipient” means receivers of WHO Pathogen Access and Benefit-Sharing (WHO PABS)
Material from the WHO coordinated laboratory network, such as manufacturers of vaccines,
diagnostics, pharmaceuticals and other products relevant to pandemic prevention, preparedness
and response, as well as biotechnology firms, research institutions and academic institutions. Any
manufacturer that enters into any contracts or formal agreements with recipients or laboratories
in the WHO coordinated network for the purpose of using WHO PABS Material on the
manufacturer’s behalf for commercialization, public use or regulatory approval of that
manufacturer’s vaccines, diagnostics or pharmaceuticals shall also be considered a recipient for
purposes of this Agreement;
(k) “universal health coverage” means that all people have access to the full range of quality
health services they need, when and where they need them, without financial hardship. It covers
the full continuum of essential health services, from health promotion to prevention, treatment,
rehabilitation and palliative care;
(l) “WHO coordinated laboratory network” means the international network of laboratories,
coordinated by WHO, that conduct year-round surveillance of pathogens with pandemic potential,
assessing the risk of an emerging pathogen with pandemic potential and assisting in pandemic
preparedness measures; and
(m) “WHO PABS Material” means a pathogen with pandemic potential, as defined herein, and
the genetic sequence data of such pathogens with pandemic potential.
Article 2. Objective and scope
1. The objective of the WHO Pandemic Agreement, guided by equity, the right to health and the
principles and approaches set forth herein, is to prevent, prepare for and respond to pandemics, with the
aim of comprehensively and effectively addressing the systemic gaps and challenges that exist in these
areas, at national, regional and international levels.
A/INB/7/3
7
2. In furtherance of its objective, the WHO Pandemic Agreement applies at all times.
Article 3. General principles and approaches
To achieve the objective of the WHO Pandemic Agreement and to implement its provisions, the
Parties will be guided, inter alia, by the general principles and approaches set forth below.
1. Respect for human rights – The implementation of this Agreement shall be with full respect for
the dignity, human rights and fundamental freedoms of persons.
2. Sovereignty – States have, in accordance with the Charter of the United Nations and the general
principles of international law, the sovereign right to legislate and to implement legislation in pursuance
of their health policies.
3. Equity – Equity is at the centre of pandemic prevention, preparedness and response, both at the
national level within States and at the international level between States. It requires, inter alia, specific
measures to protect persons in vulnerable situations. Equity includes the unhindered, fair, equitable and
timely access to safe, effective, quality and affordable pandemic-related products and services,
information, pandemic-related technologies and social protection.
4. Responsibility – Governments have a responsibility for the health of their peoples, and effective
pandemic prevention, preparedness and response require global collective action.
5. Recognition of different levels of capacity – Countries have varying levels of pandemic
prevention, preparedness and response capacities, which presents a common danger such that support
to countries with capacity needs is required, within the means and resources available.
6. Solidarity – Effective national, international, multilateral, bilateral and multisectoral
collaboration, coordination and cooperation to achieve the common interest of a safer, fairer, more
equitable and better prepared world to prevent, respond to and recover from pandemics.
7. Transparency – The effective prevention of, preparedness for and response to pandemics
depends on the transparent, open and timely sharing of, access to and disclosure of accurate information,
data and other relevant elements that may come to light, for risk assessment, prevention and control
measures, and the research and development of pandemic-related products and services, including
reports on sales revenues, prices, units sold, marketing costs and subsidies and incentives, consistent
with national, regional and international privacy and data protection rules, regulations and laws.
8. Accountability – States are accountable for strengthening and sustaining their health systems’
capacities and public health functions to provide adequate public health and social measures by adopting
and implementing legislative, executive, administrative and other measures for fair, equitable, effective
and timely pandemic prevention, preparedness and response. States are accountable to provide specific
measures to protect persons in vulnerable situations.
9. Inclusiveness – The full and active engagement with, and participation of, communities and
relevant stakeholders across all levels, consistent with relevant and applicable international and national
guidelines, rules and regulations, including those relating to conflicts of interest, is essential to mobilize
social capital, resources and adherence to public health and social measures, and to gain trust in
governments and partners supporting pandemic prevention, preparedness and response.
A/INB/7/3
8
10. Science and evidence – The best available science and evidence should inform and be the basis
for pandemic prevention, preparedness and response, as well as public health decisions and development
of plans.
11. Proportionality – Public health decisions for preventing, preparing for and responding to
pandemics should be proportionate in a manner consistent with Article 2 of the International Health
Regulations.
12. Privacy, data protection and confidentiality – Implementation of this Agreement shall respect
the right to privacy, including as such right is established under international law, and shall be consistent
with each Party’s national laws and international obligations regarding confidentiality, privacy and data
protection, as applicable.
Chapter II. The world together equitably: Achieving equity in, for and through
pandemic prevention, preparedness and response
Article 4. Pandemic prevention and public health surveillance
1. The Parties shall cooperate with one another, in bilateral, regional and multilateral settings, in the
development and strengthening of pandemic prevention and public health surveillance capacities.
2. The Parties should take actions to strengthen multisectoral, coordinated data interoperability and
support the adoption of relevant international data standards in the development of pandemic prevention
and public health surveillance capacities, with particular regard to the strengthening of developing
countries’ capacities.
3. The Parties shall cooperate, with the support of the WHO Secretariat, to strengthen and maintain
public health laboratory and diagnostic capacities, especially in respect of the capacity to perform
genetic sequencing, data science to assess the risks of detected pathogens and to safely handle samples
containing pathogens, and the use of related digital tools.
4. Each Party shall develop, strengthen, implement, periodically update and review comprehensive
multisectoral national pandemic prevention and public health surveillance plans that are consistent with
and supportive of the effective implementation of the International Health Regulations. To this end, each
Party shall, in accordance with its capabilities:
(a) develop, strengthen and maintain capacity to: (i) detect, identify and characterize pathogens
presenting significant risks; and (ii) conduct risk assessments of such pathogens and vector-borne
diseases to prevent spill-over in human and animal populations and cause serious diseases leading
to pandemic situations;
(b) strengthen efforts to ensure access to safe water, sanitation and hygiene, including in hard-
to-reach settings in the Party’s territory;
(c) ensure the implementation of effective infection prevention and control measures, applying
as far as possible the applicable international standards and guidelines;
(d) strengthen efforts to ensure the sound management of wastes from health facilities and
require health care institutions to have in place a regularly updated infection prevention and
control programme;
A/INB/7/3
9
(e) strengthen animal disease preventive measures and monitor and mitigate environmental
factors associated with the risk of zoonotic disease spill-over and spill-back;
(f) strengthen laboratory biosafety and biosecurity, including in research facilities, in order to
prevent the accidental exposure, misuse or inadvertent laboratory release of pathogens, through
biosecurity training and practices, regulating access to sensitive locations and strengthening
transportation security and cross-border transfer, in accordance with applicable rules and
standards; and
(g) take actions to prevent outbreaks due to pathogens that are resistant to antimicrobial agents,
and, in accordance with national context, develop and implement a national One Health action
plan that includes an antimicrobial resistance component.
5. Each Party shall develop, strengthen and maintain capacity to carry out integrated public health
surveillance, including in respect of infectious diseases in humans, and animals that present significant
risks of zoonotic diseases spill-over.
Article 5. One Health
1. The Parties commit to promote and implement a One Health approach for pandemic prevention,
preparedness and response that is coherent, integrated, coordinated and collaborative among all relevant
actors, with the application of, and in accordance with, national law.
2. The Parties shall promote and enhance synergies between multisectoral and transdisciplinary
collaboration at the national level and cooperation at the international level, in order to identify and
conduct risk assessments at the interface between human, animal and environment ecosystems, while
recognizing their interdependence, and with applicable sharing of the benefits, per the terms of
Article 12 herein.
3. The Parties commit to identify and address the drivers of pandemics and the emergence and re-
emergence of disease at the human-animal-environment interface through the identification and
integration of interventions into relevant pandemic prevention, preparedness plans, and, where
appropriate, according to national legislation and capacity, through the strengthening of synergies with
other relevant instruments.
4. Each Party shall, in accordance with national context and to the extent necessary, protect human,
animal and plant health by:
(a) implementing science-based actions, including but not limited to: improving infection
prevention and control measures; antimicrobial research and development; access to and
stewardship of antimicrobials; and harmonization of surveillance, in order to prevent, reduce the
risk of, and prepare for, pandemics;
(b) fostering and implementing actions at national and community levels that encompass
whole-of-government and whole-of-society approaches to control zoonotic outbreaks, including
through the engagement of communities in surveillance to identify zoonotic outbreaks;
(c) taking a One Health approach into account in order to produce science-based evidence,
including that which is related to social and behavioural sciences, and risk communication and
community engagement; and
A/INB/7/3
10
(d) promoting or establishing One Health joint training and continuing education programmes
for human, animal and environmental health workforces, needed to build complementary skills,
capacities and capabilities to prevent, detect, control and respond to pandemic health threats.
5. The Parties commit to develop, within the framework of relevant institutions, international norms
and guidelines to prevent zoonoses.
6. Pursuant to Article 21 herein, the Conference of the Parties shall develop appropriate modalities
to address the measures set forth in Articles 4 and 5 of this Agreement.
7. The Parties shall, in line with Article 16 herein, develop and implement or strengthen, as
appropriate, bilateral, regional, subregional and other multilateral channels to enhance financial and
technical support, assistance and cooperation, in particular in respect of developing countries, to
strengthen surveillance systems and laboratory capacity in respect of promoting and implementing a
One Health approach at the national level.
Article 6. Preparedness, readiness and resilience
1. Each Party shall continue to strengthen its health system, including primary health care, for
sustainable pandemic prevention, preparedness and response, taking into account the need for equity
and resilience, with a view to the progressive realization of universal health coverage.
2. Each Party shall, in accordance with applicable laws, including, where appropriate, the
International Health Regulations, adopt policies, strategies and/or measures, as appropriate, and
strengthen and reinforce public health functions for:
(a) the continued provision of quality routine and essential health services during pandemics;
(b) sustaining and strengthening the capacities of the multidisciplinary workforce needed
during interpandemic periods, and preparing for and ensuring surge capacity during pandemics;
(c) collaborative surveillance, outbreak detection, investigation and control, through
interoperable early warning and alert systems, and timely notification;
(d) multisectoral prevention of zoonoses, epidemic-prone diseases and emerging, growing or
evolving public health threats with pandemic potential, notably at the human-animal-environment
interface;
(e) the development of rehabilitation and post-pandemic health system recovery strategies;
(f) strengthening public health laboratory and diagnostic capacities, and national, regional and
global networks, through the application of standards and protocols for public health laboratory
biosafety and biosecurity;
(g) creating and maintaining up-to-date, universal, interconnected platforms and technologies
for early detection, forecasting and timely information sharing, through appropriate capacities,
including building digital health and data science capacities;
(h) creating and strengthening public health institutions at national, regional and international
levels;
A/INB/7/3
11
(i) strengthening public health emergency operations centres’ capacities during interpandemic
and pandemic periods; and
(j) strengthening infection prevention and control.
3. The Parties shall cooperate, within available means and resources, to provide financial, technical
and technological support, assistance, capacity-strengthening and cooperation, in particular in respect
of developing countries, in order to strengthen health emergency prevention, preparedness and response
and health system recovery, consistent with the goal of universal health coverage.
4. The Parties shall establish, building on existing arrangements as appropriate, genomics, risk
assessment and laboratory networks in order to conduct surveillance and sharing of emerging pathogens
with pandemic potential, pursuant to the terms and modalities established in Article 12 herein.
Article 7. Health and care workforce
1. Each Party, in line with its respective capacities, shall take the necessary steps to safeguard,
protect, invest in and sustain a skilled, trained, competent and committed health and care workforce,
with the aim of increasing and sustaining capacities for pandemic prevention, preparedness and
response, while maintaining quality essential health services and essential public health functions during
pandemics. To this end, each Party shall, in accordance with national law:
(a) strengthen, pre-, in- and post-service competency-based education and training,
deployment, remuneration, distribution and retention of the public health, health and care
workforce, including community health workers and volunteers;
(b) address gender and youth disparities and inequalities and security concerns within the
public health, health and care workforce, particularly in health emergencies, to support the
meaningful representation, engagement, participation, empowerment, safety and well-being of all
health and care workers, while addressing discrimination, stigma and inequality and eliminating
bias, including unequal remuneration, and noting that women still often face significant barriers
to reaching leadership and decision-making roles;
(c) strengthen efforts to address the safety of the health and care workforce, including by
ensuring priority access to pandemic-related products during pandemics, minimizing disruptions
to the delivery of good quality essential health services, and developing and integrating effective
measures to prevent and address violence and threats against health and care workers, their means
of transport and equipment, as well as hospitals and other medical facilities, when preventing and
responding to pandemics; and
(d) establish and maintain effective workforce planning systems to effectively and efficiently
deploy trained health and care workers during pandemics.
2. The Parties shall commit financial and technical support, assistance and cooperation, in particular
in respect of developing countries, in order to strengthen and sustain a skilled and competent public
health, health and care workforce at subnational, national and regional levels.
3. The Parties shall invest in establishing, sustaining, coordinating and mobilizing a skilled and
trained multidisciplinary global public health emergency workforce that is deployable to support Parties
upon request, based on public health need, in order to contain outbreaks and prevent the escalation of a
small-scale spread to global proportions.
A/INB/7/3
12
4. The Parties shall develop a network of training institutions, national and regional facilities, and
centres of expertise to strengthen and sustain a skilled and competent public health, health and care
workforce at subnational, national and regional levels.
Article 8. Preparedness monitoring and functional reviews
1. Each Party shall, in accordance with national laws and in the light of national context, develop
and implement comprehensive, inclusive, multisectoral, resourced national plans and strategies for
pandemic prevention, preparedness and response and health system recovery.
2. Each Party shall assess, no less than every five years, with technical support from the WHO
Secretariat upon request, the functioning and readiness of, and gaps in, its pandemic preparedness,
surveillance and multisectoral response capacity, logistics and supply chain management, and risk
assessment, and shall support the conduct of, inter alia, appropriate simulation or tabletop exercises, and
intra- and after-action reviews, based on the relevant tools and guidelines developed by WHO in
partnership with relevant organizations.
3. The Parties shall, building on existing tools, develop and implement an inclusive, transparent,
effective and efficient pandemic prevention, preparedness and response monitoring and evaluation
system.
4. The Parties shall establish, no later than 31 December 2026, a global peer review mechanism to
assess pandemic prevention, preparedness and response capacities and gaps, as well as levels of
readiness, with the aim of promoting and supporting learning among Parties, best practices, actions and
accountability, at the national, regional and global levels, to strengthen national health emergency
preparedness and readiness capacities.
Article 9. Research and development
1. The Parties shall cooperate to build, strengthen and sustain geographically diverse capacities and
institutions for research and development, particularly in developing countries, and shall promote
research collaboration and access to research through open science approaches for the rapid sharing of
information and results.
2. To this end, the Parties shall promote:
(a) sustained investment in the research and development of public health priorities, including
for pandemic-related products, aimed at improving equitable access to and delivery of such
products, and support for national and regional research institutions that can rapidly adapt and
respond to research and development needs in case of a pandemic;
(b) technology co-creation and joint venture initiatives, actively engaging the participation of
and collaboration among scientists and/or research centres, particularly from developing
countries;
(c) participation of relevant stakeholders, consistent with applicable biosafety and biosecurity
obligations, laws, regulations and guidance, to accelerate innovative research and development,
including community-led and cross-sector collaboration, for addressing emerging and
re-emerging pathogens with pandemic potential; and
A/INB/7/3
13
(d) knowledge translation and evidence-based communication tools, strategies and
partnerships relating to pandemic prevention, preparedness and response, including infodemic
management, at local, national, regional and international levels.
3. The Parties shall, in accordance with national laws and regulatory frameworks and contexts, take
steps to develop and sustain strong, resilient and appropriately resourced, national, regional and
international research capabilities. To this end, the Parties shall:
(a) increase clinical trial capacities, including by:
(i) building and maintaining a skilled research workforce and infrastructure, as
appropriate;
(ii) strengthening clinical trial policy frameworks, particularly in developing countries;
(iii) investing in the infrastructure and training of clinical research networks and the
coordination of clinical trials through existing, new or expanded clinical trial networks,
including in developing countries, to be prepared to provide timely and appropriate
responses to pandemics; and
(iv) identifying and researching supply chain needs to rapidly mount and scale research
responses during pandemic emergencies.
(b) ensure that clinical trials have equitable representation, considering racial, ethnic and
gender diversity across the life cycle, and are designed to help to address geographical,
socioeconomic and health disparities, to promote a better understanding of the safety and efficacy
of pandemic-related products for population subgroups;
(c) promote the sharing of information on national research agendas, including research and
development priorities during pandemic emergencies, capacity-building activities and best
practices on efficient and ethical clinical trials, including through the WHO Global Observatory
on Health Research and Development;
(d) strengthen international coordination and collaboration in respect of clinical trials, through
existing or new mechanisms, to support well-designed and well-implemented clinical trials;
(e) develop national policies to support the transparent, public sharing of clinical trial protocols
and results conducted either within their territories or through partnerships with other Parties,
such as through open access publications, while protecting privacy and health identifiers; and
(f) support new and existing mechanisms to facilitate the rapid reporting and interpretation of
data from clinical trials, to develop or modify, as necessary, relevant clinical trial guidelines,
including during a pandemic.
A/INB/7/3
14
4. Each Party shall, in accordance with national laws and considering the extent of public funding
provided, publish the terms of government-funded research and development agreements for pandemic-
related products, including information on:
(a) research inputs, processes and outputs, including scientific publications and data
repositories, with data shared and stored securely in alignment with findability, accessibility,
interoperability and reusability principles;
(b) the pricing of end-products, or pricing policies for end-products;
(c) licensing to enable the development, manufacturing and distribution of pandemic-related
products, especially in developing countries; and
(d) terms regarding affordable, equitable and timely access to pandemic-related products
during a pandemic.
Article 10. Sustainable production
1. The Parties, with a view to achieving a more equitable geographical distribution of the global
production of pandemic-related products, and increasing timely, fair and equitable access to safe,
effective, quality and affordable pandemic-related products, thereby reducing the potential gap between
supply and demand at the time of a pandemic, shall:
(a) take measures to identify and maintain production facilities at national and regional levels,
as well as to facilitate the production, as appropriate, and in furtherance of the provisions of
Article 13 herein, of pandemic-related products therein;
(b) take measures to identify and contract with manufacturers other than those referenced in
paragraph 1(a) of this Article, for scaling up the production of pandemic-related products, during
pandemics, in cases where the production and supply capacity of the production facilities does
not meet demand;
(c) strengthen coordination with relevant international organizations, including United Nations
entities, on issues related to public health, intellectual property and trade, including the timely
matching of supply to demand and mapping manufacturing capacities and demand;
(d) encourage entities, including manufacturers within their respective jurisdictions, in
particular those that receive significant public financing, to grant, subject to any existing licensing
restrictions, on mutually agreed terms, non-exclusive, royalty-free licences to any manufacturers,
particularly from developing countries, to use their intellectual property and other protected
substances, products, technology, know-how, information and knowledge used in the process of
pandemic-related product development and production, in particular for pre-pandemic and
pandemic diagnostics, vaccines and therapeutics for use in agreed developing countries;
(e) actively support, participate in and/or implement, as appropriate, relevant WHO
technology, skills and know-how transfer programmes and initiatives aimed at enabling
developing countries to produce pandemic-related products, in order to facilitate strategically and
geographically distributed production of pandemic-related products; and
A/INB/7/3
15
(f) support public and private sector investments aimed at creating or expanding
manufacturing facilities for pandemic-related products, especially facilities with a regional
operational scope that are based in developing countries.
2. Each Party shall initiate or strengthen, as appropriate, the conduct of disease burden studies
relevant to pathogens with pandemic potential, with a view to ensuring the sustainability of investments
in facilities for the production of vaccines and therapeutics that could support pandemic response.
3. Each Party, in addition to the undertakings in paragraph 2 of this Article, shall:
(a) encourage research and development institutes and manufacturers, in particular those
receiving significant public financing, to waive or manage, for a limited duration, royalties on the
use of their technology for the production of pandemic-related products;
(b) promote the publication, by private rights holders, of the terms of licensing agreements or
technology transfer agreements for pandemic-related products; and
(c) promote the voluntary licensing and transfer of technology and related know-how for
pandemic-related products by private rights holders with established regional or global
technology transfer hubs or other multilateral mechanisms or networks.
Article 11. Transfer of technology and know-how
1. The Parties, within a set time frame, working through the Conference of the Parties, shall
strengthen existing, and develop innovative, multilateral mechanisms, including through the pooling of
knowledge, intellectual property and data, that promote the transfer of technology and know-how for
the production of pandemic-related products, on mutually agreed terms as appropriate, to manufacturers,
particularly in developing countries.
2. The Parties shall:
(a) coordinate with, collaborate with, facilitate and incentivize the manufacturers of
pandemic-related products to transfer relevant technology and know-how to manufacturer(s) on
mutually agreed terms as appropriate, including through technology transfer hubs and product
development partnerships, and to address the need to develop new pandemic-related products in
a short time frame;
(b) make available non-exclusive licensing of government-owned technologies, on mutually
agreed terms as appropriate, for the development and manufacturing of pandemic-related
products, and publish the terms of these licences;
(c) make use of the flexibilities provided in the Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS Agreement), including those recognized in the Doha
Declaration on the TRIPS Agreement and Public Health and in Articles 27, 30 (including the
research exception and “Bolar” provision), 31 and 31bis of the TRIPS Agreement, and fully
respect the use thereof by others;
(d) collaborate to ensure equitable and affordable access to health technologies that promote
the strengthening of national health systems and mitigate social inequalities;
A/INB/7/3
16
(e) develop a database that provides the details of pandemic-related products for all known
pandemic-potential diseases, including the technological specifications and manufacturing
process documents for each product; and
(f) provide, within their capabilities, resources to support capacity-building for the
development and transfer of relevant technology, skills and know-how, and to facilitate access to
other sources of support.
3. During pandemics, each Party shall, in addition to the undertakings in paragraph 2 of this Article:
(a) commit to agree upon, within the framework of relevant institutions, time-bound waivers
of intellectual property rights to accelerate or scale up the manufacturing of pandemic-related
products to the extent necessary to increase the availability and adequacy of affordable pandemic-
related products;
(b) encourage all holders of patents related to the production of pandemic-related products to
waive or manage, as appropriate, for a limited duration, the payment of royalties by developing
country manufacturers on the use, during the pandemic, of their technology for the production of
pandemic-related products, and shall require, as appropriate, those that have received public
financing for the development of pandemic-related products to do so; and
(c) encourage manufacturers within its jurisdiction to share undisclosed information, in
accordance with paragraph 2 of Article 39 of the TRIPS Agreement, with qualified third-party
manufacturers when the withholding of such information prevents or hinders urgent manufacture
by qualified third parties of a pharmaceutical product that is necessary to respond to the pandemic.
4. The Parties shall, with a view to effective pandemic response, when engaged in bilateral or
regional trade or investment negotiations, take steps so that the negotiated provisions do not interfere
with the full use of the flexibilities provided in the TRIPS Agreement, including those recognized in the
Doha Declaration on the TRIPS Agreement and Public Health.
Article 12. Access and benefit sharing
1. The Parties hereby establish a multilateral system for access and benefit sharing, on an equal
footing, the WHO Pathogen Access and Benefit-Sharing System (WHO PABS System), to ensure rapid
and timely risk assessment and facilitate rapid and timely development of, and equitable access to,
pandemic-related products for pandemic prevention, preparedness and response.
2. The WHO PABS System shall ensure rapid, systematic and timely sharing of WHO PABS
Material, as well as, on an equal footing, timely, effective, predictable and equitable access to pandemic-
related products, and other benefits, both monetary and non-monetary, based on public health risks and
needs, to strengthen pandemic prevention, preparedness and response.
3. The Parties shall implement the WHO PABS System:
(a) in a manner to strengthen, expedite and not impede research and innovation;
(b) at all times, both during and between pandemics;
(c) in a manner to ensure mutual complementarity with the Pandemic Influenza Preparedness
Framework; and
A/INB/7/3
17
(d) with governance and review mechanisms, to be determined by the Conference of the
Parties.
4. The WHO PABS System shall have the following components:
(a) WHO PABS Materials sharing:
(i) Each Party, through its relevant public health authorities and authorized laboratories,
shall, in a rapid, systematic and timely manner: (1) provide WHO PABS Material to a
laboratory recognized or designated as part of an established WHO coordinated laboratory
network; and (2) upload the genetic sequence of such WHO PABS Material to one or more
publicly accessible database(s) of its choice, provided that the database has put in place an
appropriate arrangement in respect of WHO PABS Materials.
(ii) The WHO PABS System shall be consistent with international legal frameworks,
notably those for the collection of patient specimens, material and data, and will promote
findable, accessible, interoperable and reusable data available to all Parties.
(iii) The Parties shall develop and use a Standard Material Transfer Agreement (a PABS
SMTA), which may be concluded through electronic means, and which shall include
relevant biosafety and biosecurity rules, to be used with the transfer of WHO PABS
Materials from a laboratory recognized or designated as part of an established WHO
coordinated laboratory network to any Recipient.
(iv) Recipients of WHO PABS Material shall not seek to obtain any intellectual rights
on WHO PABS Material.
(b) PABS multilateral benefit sharing:
(i) Benefits, both monetary and non-monetary, arising from access to WHO PABS
Materials, shall be shared fairly and equitably, pursuant to a PABS SMTA, which may be
concluded through electronic means.
(ii) The PABS SMTAs shall include, but not be limited to, the following monetary and
non-monetary benefit-sharing obligations:
(a) in the event of a pandemic, real-time access by WHO to a minimum of 20%
(10% as a donation and 10% at affordable prices to WHO) of the production of safe,
efficacious and effective pandemic-related products for distribution based on public
health risks and needs, with the understanding that each Party that has manufacturing
facilities that produce pandemic-related products in its jurisdiction shall take all
necessary steps to facilitate the export of such pandemic-related products, in
accordance with timetables to be agreed between WHO and manufacturers; and
(b) on an annual basis, contributions from Recipients, based on their nature and
capacity, to the capacity development fund of the sustainable funding mechanism
established in Article 20 herein.
A/INB/7/3
18
(c) The Parties shall also consider additional benefit-sharing options, including:
(i) encouraging manufacturers from developed countries to collaborate with
manufacturers from developing countries through WHO initiatives to transfer technology
and know-how and strengthen capacities for the timely scale-up of production of pandemic-
related products;
(ii) tiered-pricing or other cost-related arrangements, such as no loss/no profit loss
arrangements, for purchase of pandemic-related products, that consider the income level of
countries; and
(iii) encouraging of laboratories in the WHO coordinated laboratory network to actively
seek the participation of scientists from developing countries in scientific projects
associated with research on WHO PABS Materials.
5. In the event that pandemic-related products are produced by a manufacturer that does not have a
PABS SMTA under the WHO PABS System, it shall be understood that the production of
pandemic-related products requiring the use of WHO PABS Materials, implies the use of the WHO
PABS System. Accordingly, each Party, in respect of such a manufacturer operating within its
jurisdiction, shall take all appropriate steps, in accordance with its relevant laws and circumstances, to
require such a manufacturer to provide benefits in accordance with paragraph 4(b)(ii) of this Article.
6. The Parties shall develop a mechanism to ensure the fair and equitable allocation of pandemic-
related products, based on public health risks and needs.
7. The Parties shall ensure that all components of the WHO PABS System are operational no later
than 31 May 2025. The Parties shall review the operation and functioning of the WHO PABS System
every five years.
8. The Parties shall ensure that the WHO PABS System is consistent with, supportive of and does
not run counter to the objectives of the Convention on Biological Diversity and the Nagoya Protocol on
Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their
Utilization thereto. The WHO PABS System will provide certainty and legal clarity to the providers and
users of WHO PABS Materials. The WHO PABS System shall be recognized as a specialized
international access and benefit-sharing instrument within the meaning of paragraph 4 of Article 4 of
the Nagoya Protocol.
Article 13. Global Supply Chain and Logistics Network
1. The WHO Global Supply Chain and Logistics Network (the WHO SCL Network) is hereby
established. The WHO SCL Network will operate within the framework of WHO, in partnership and
collaboration with relevant international, regional and other organizations, and be guided by equity and
public health needs, paying particular attention to the needs of developing country Parties.
2. The Conference of the Parties shall develop guidelines on modalities and collaboration for the
WHO SCL Network, which shall be aimed at ensuring close consultation among Parties and that
functions are discharged by the organizations best placed to perform them.
A/INB/7/3
19
3. The Parties shall support the WHO SCL Network’s development and operationalization and
participate in the WHO SCL Network, including through sustaining it at all times. The terms of the
WHO SCL Network shall include:
(a) estimating, or, where possible, determining, the most likely types and size/volume of
products needed for robust pandemic prevention, preparedness and response, including the costs
and logistics for establishing and maintaining strategic stockpiles of such products;
(b) assessing the anticipated demand for, mapping the sources of and maintaining a dashboard
of manufacturers and suppliers, including surge capacities and relevant necessary raw materials,
for the sustainable production of pandemic-related products;
(c) identifying the most efficient multilateral and regional purchasing mechanisms, including
pooled mechanisms;
(d) working with national authorities to establish and maintain national and/or regional
stockpiles of various pandemic response-related products, as well as maintaining the relevant
logistic capacities and assessing them at regular intervals, and specifying the criteria to ensure
that stockpiling is used only to address public health needs;
(e) facilitating the negotiation and agreement of advance purchase commitments and
procurement contracts for pandemic-related products;
(f) promoting transparency in cost, pricing and all other relevant contractual terms along the
supply chain;
(g) coordinating to avoid competition for resources among procuring entities, including
regional organizations and/or mechanisms;
(h) mapping existing, and identifying needed, delivery and distribution options;
(i) establishing or operationalizing, as appropriate, international or regional stockpiles,
consolidation hubs and staging areas;
(j) assisting buying countries in meeting the logistic requirements for the utilization of specific
pandemic-related products; and
(k) facilitating or, as necessary, organizing the efficient delivery and appropriate utilization of
pandemic-related products in beneficiary countries or in humanitarian settings.
4. Each Party shall take appropriate measures to reduce waste of pandemic-related products,
including through the exchange and/or donation of products in order to maximize their use, while taking
account of the needs of recipient countries.
5. Each Party shall, at the earliest reasonable opportunity and in accordance with applicable laws,
make publicly available online the terms of government-funded purchase agreements for
pandemic-related products in those instances in which the Party is directly entering into such purchase
agreements.
A/INB/7/3
20
6. Each Party shall, in its government-funded purchase agreements for pandemic-related products,
to the fullest extent possible and in accordance with applicable laws, exclude confidentiality provisions
that serve to limit the disclosure of terms and conditions.
7. The Parties recognize that any emergency trade measures in the event of a pandemic shall be
targeted, proportionate, transparent and temporary, and do not create unnecessary barriers to trade or
unnecessary disruptions in supply chains.
8. The Parties shall commit to ensure rapid and unimpeded access of humanitarian relief personnel,
as well as their means of transport, supplies and equipment, in accordance with international
humanitarian law, and to respect the principles of humanity, neutrality, impartiality and independence
for the provision of humanitarian assistance.
9. The Parties shall enable inclusive, equitable and effective cooperation and participation, and shall
take all appropriate measures to undertake the foregoing no later than 31 May 2025.
Article 14. Regulatory strengthening
1. The Parties shall strengthen their national and regional regulatory authorities, including through
technical assistance, with the aim of expediting regulatory approvals and authorizations and ensuring
the quality, safety and efficacy of pandemic-related products.
2. The Parties shall align and, where possible, harmonize technical and regulatory requirements and
procedures, in accordance with applicable international standards, guidance and protocols, including
those covering regulatory reliance and mutual recognition, and share relevant information and
assessments concerning the quality, safety and efficacy of pandemic-related products with other Parties.
3. The Parties shall, as appropriate, monitor, regulate and strengthen rapid alert systems against
substandard and falsified pandemic-related products.
4. Each Party shall, in accordance with relevant laws, publicly disclose information on national and,
if applicable, regional processes for authorizing or approving use of pandemic-related products, and any
additional relevant regulatory pathways for such pandemic-related products that may be activated during
a pandemic to increase efficiency, and update such information in a timely manner.
5. Each Party shall take steps to ensure that it has the legal, administrative and financial frameworks
in place to support emergency regulatory approvals for the effective and timely regulatory approval of
pandemic-related products during a pandemic.
6. Each Party shall, in accordance with relevant laws, encourage manufacturers to generate relevant
data, contribute to the development of common technical documents, and diligently pursue regulatory
authorizations and/or approvals of pandemic-related products with WHO listed authorities, other
priority authorities and WHO.
Article 15. Compensation and liability management
1. Each Party shall develop national strategies for managing liability risks in its territory regarding
the manufacturing, distribution, administration and use of novel vaccines developed in response to
pandemics. Strategies may include, inter alia, the development of model contract provisions, vaccine
injury compensation mechanisms, insurance mechanisms, policy frameworks and principles for the
A/INB/7/3
21
negotiation of procurement agreements and/or the donation of novel vaccines developed in response to
pandemics, and building expertise for contract negotiations in this matter.
2. The Conference of the Parties shall establish, within two years of the entry into force of the WHO
Pandemic Agreement, using existing relevant models as a reference, no-fault vaccine injury
compensation mechanism(s), with the aim of promoting access to financial remedy for individuals
experiencing serious adverse events resulting from a pandemic vaccine, as well as more generally
promoting pandemic vaccine acceptance. The Conference of the Parties shall further develop the
mechanism(s), which may be regional and/or international, including strategies for funding the
mechanism(s), through the modalities provided for in Article 20 herein.
3. Each Party shall endeavour to ensure that, in contracts for the supply or purchase of novel
pandemic vaccines, buyer/recipient indemnity clauses, if any, are exceptionally provided and are time-
bound.
Article 16. International collaboration and cooperation
1. The Parties shall collaborate and cooperate with competent international and regional
intergovernmental organizations and other bodies, as well as among themselves, in the formulation of
cost-effective measures, procedures and guidelines for pandemic prevention, preparedness and response.
2. The Parties shall:
(a) promote global, regional and national political commitment, coordination and leadership
for pandemic prevention, preparedness and response;
(b) support mechanisms that ensure that policy decisions are science- and evidence-based;
(c) develop, as necessary, and implement policies that respect, protect and fulfil the human
rights of all people;
(d) promote equitable representation on the basis of gender, geographical and socioeconomic
status, as well as the equal and meaningful participation of young people and women;
(e) assist developing countries through multilateral and bilateral partnerships that focus on
developing capacities for effectively addressing health needs for pandemic prevention,
preparedness and response in line with the provisions set forth in Article 19 herein; and
(f) encourage ceasefires in affected countries during pandemics to promote global cooperation
against common global threats.
Article 17. Whole-of-government and whole-of-society approaches at the national level
1. The Parties are encouraged to adopt whole-of-government and whole-of-society approaches,
including to empower and ensure community ownership of, and contribution to, community readiness
for and resilience to pandemic prevention, preparedness and response.
2. Each Party shall, in keeping with national capacities, establish, implement and adequately finance
an effective national coordinating multisectoral mechanism.
A/INB/7/3
22
3. Each Party shall, in accordance with national context, promote the effective and meaningful
engagement of communities, civil society and other relevant stakeholders, including the private sector,
as part of a whole-of-society approach in decision-making, implementation, monitoring and evaluation,
and shall also provide effective feedback opportunities.
4. Each Party shall develop, in accordance with national context, comprehensive national pandemic
prevention, preparedness and response plans pre-, post- and interpandemic that, inter alia:
(a) identify and prioritize populations for access to pandemic-related products and health
services;
(b) support the timely and scalable mobilization of the multidisciplinary surge capacity of
human and financial resources, and facilitate the timely allocation of resources to the frontline
pandemic response;
(c) review the status of stockpiles and the surge capacity of essential public health and clinical
resources, and surge capacity in the production of pandemic-related products;
(d) facilitate the rapid and equitable restoration of public health capacities and routine and
essential health services following a pandemic; and
(e) promote collaboration with relevant stakeholders, including the private sector and civil
society.
5. Each Party, based on national capacities, shall take the necessary steps to address the social,
environmental and economic determinants of health, and the vulnerability conditions that contribute to
the emergence and spread of pandemics, and shall prevent or mitigate the socioeconomic impacts of
pandemics.
6. Each Party shall take appropriate measures to strengthen national public health and social policies
to facilitate a rapid, resilient response to pandemics, especially for persons in vulnerable situations,
including by mobilizing social capital in communities for mutual support.
Article 18. Communication and public awareness
1. The Parties shall strengthen science, public health and pandemic literacy in the population, as
well as access to information on pandemics and their effects and drivers, and combat false, misleading,
misinformation or disinformation, including through effective international collaboration and
cooperation as referred to in Article 16 herein.
2. The Parties shall, as appropriate, conduct research and inform policies on factors that hinder
adherence to public health and social measures in a pandemic and trust in science and public health
institutions.
3. The Parties shall promote and apply a science- and evidence-informed approach to effective and
timely risk assessment and public communication.
Article 19. Implementation capacities and support
1. The Parties shall cooperate, directly or through competent international bodies, to strengthen their
capacity to fulfil the obligations arising from this Agreement, taking into account especially the needs
A/INB/7/3
23
of developing country Parties. Such cooperation shall promote the transfer of technical, scientific and
legal expertise and technology, as mutually agreed, to establish and strengthen the sustainable pandemic
prevention, preparedness and response capacities of all Parties.
2. Each Party shall, within the means and resources at their disposal, cooperate to raise financial
resources for the effective implementation of the WHO Pandemic Agreement through bilateral and
multilateral funding mechanisms.
3. The Parties shall give particular consideration to the specific needs and special circumstances of
developing country Parties for financial and technical assistance to support the implementation of this
Agreement.
4. The Parties shall, where a Party lacks the necessary capacity to implement specific provision(s)
of this Agreement, work together to identify the most relevant partner(s) that can support the
development of such capacities, and shall cooperate to ensure that the mechanism(s) identified in
Article 20 herein provides the necessary financial resources.
Article 20. Financing
1. The Parties commit to sustainable financing for strengthening pandemic prevention, preparedness
and response. In this regard, each Party, within the means and resources at its disposal, shall:
(a) cooperate with other Parties, as appropriate, to raise sustainable financial resources for the
effective implementation of this Agreement through bilateral and multilateral, regional or
subregional funding mechanisms;
(b) plan and provide adequate financial support, in line with national fiscal capacities,
for: (i) strengthening and sustaining capacities for pandemic prevention, preparedness and
response; (ii) implementing national plans, programmes and priorities; and (iii) strengthening
health systems and the progressive realization of universal health coverage for pandemic
prevention, preparedness and response;
(c) prioritize and increase or maintain, including through greater collaboration between the
health, finance and private sectors, as appropriate, domestic funding for pandemic prevention,
preparedness and response;
(d) mobilize financial resources for international cooperation and assistance in respect of
pandemic prevention, preparedness and response, in accordance with its capacities and based on
the principle of solidarity, particularly for developing countries, including through international
organizations and existing and new mechanisms; and
(e) provide support and assistance to other Parties, upon request, to facilitate the containment
of spill-over at the source.
2. A sustainable funding mechanism shall be established by the Conference of the Parties no later
than 31 December 2026. The mechanism shall ensure the provision of adequate, accessible, new and
additional and predictable financial resources, and shall include the following:
(a) A capacity development fund that shall be resourced, inter alia, through the following:
(i) annual monetary contributions from Parties to the WHO Pandemic Agreement;
A/INB/7/3
24
(ii) monetary contributions from recipients pursuant to Article 12 herein; and
(iii) voluntary monetary contributions from Parties to the WHO Pandemic Agreement.
(b) An endowment for pandemic prevention, preparedness and response, resourced, inter alia,
through the following:
(i) voluntary monetary contributions from all relevant sectors that benefit from
international work to strengthen pandemic prevention, preparedness and response; and
(ii) donations from philanthropic organizations and foundations, and other voluntary
monetary contributions.
(c) The funding mechanism will provide resources to assist Parties, in particular developing
countries, in meeting their obligations under the WHO Pandemic Agreement and related activities
for pandemic prevention, preparedness and response. The funding mechanism will contribute to
funding support of the Secretariat of the WHO Pandemic Agreement.
(d) For the purposes of this Agreement, the mechanism shall function under the authority of
the Conference of the Parties, and shall be accountable thereto. The Conference of the Parties
shall further define and provide guidance on overall strategies, policies, programme priorities and
eligibility for access to and utilization of financial resources, including in respect of the
compensation mechanism(s) referred to in Article 15 herein, and shall also monitor outcomes and
address the operation and resourcing of the funding mechanism, with due regard to the avoidance
of conflicts of interest.
3. The Parties represented in relevant regional and international intergovernmental organizations
and financial and development institutions shall encourage, as appropriate, these entities to provide
additional financial assistance for developing country Parties to support them in meeting their
obligations under the WHO Pandemic Agreement, without limiting their participation in or membership
of these organizations.
Chapter III. Institutional arrangements and final provisions
Article 21. Conference of the Parties
1. A Conference of the Parties is hereby established. The Conference of the Parties shall be
comprised of delegates representing the Parties to the WHO Pandemic Agreement. Only delegates
representing Parties will participate in any of the decision-making of the Conference of the Parties. The
Conference of the Parties shall establish the criteria for the participation of observers at its proceedings.
2. With the aim of promoting the coherence of the Conference of the Parties and the Health
Assembly, as well as coherence in respect of relevant instruments and mechanisms within the framework
of the World Health Organization, the Conference of the Parties shall operate in coordination with the
Health Assembly. In particular, the Conference of the Parties shall hold its regular sessions immediately
before or after regular sessions of the Health Assembly, and in the same location and venue as the Health
Assembly, where feasible.
3. The first session of the Conference of the Parties shall be convened by the World Health
Organization not later than one year after the entry into force of the WHO Pandemic Agreement.
A/INB/7/3
25
4. Following the first session of the Conference of the Parties:
(a) subsequent regular sessions of the Conference of the Parties shall be held annually; and
(b) extraordinary sessions of the Conference of the Parties shall be held at such other times,
without reference to the regular sessions of the Health Assembly, as may be deemed necessary
by the Conference of the Parties, or at the written request of any Party, provided that, within
six months of the request being communicated to them by the Secretariat, it is supported by at
least one third of the Parties.
5. The Conference of the Parties shall adopt by consensus its Rules of Procedure at its first session.
6. The Conference of the Parties shall by consensus adopt financial rules for itself as well as
governing the funding of any subsidiary bodies of the Conference of the Parties that are or may be
established, as well as financial provisions governing the functioning of the Secretariat. It shall also
adopt a biennial budget.
7. The Conference of the Parties shall keep under regular review the implementation of the WHO
Pandemic Agreement and take the decisions necessary to promote its effective implementation, and may
adopt amendments, annexes and protocols to the WHO Pandemic Agreement, in accordance with
Articles 28, 29 and 30 herein. To this end, it shall:
(a) consider reports submitted by the Parties in accordance with Article 23 herein and adopt
regular reports on the implementation of the WHO Pandemic Agreement;
(b) oversee any subsidiary bodies, including by establishing their rules of procedure and
working modalities;
(c) promote and facilitate the mobilization of financial resources for the implementation of the
WHO Pandemic Agreement, in accordance with Article 20 herein;
(d) request, where appropriate, the services and cooperation of, and information provided by,
competent and relevant organizations and bodies of the United Nations system and other
international and regional intergovernmental organizations and nongovernmental organizations
and bodies as a means of strengthening the implementation of the WHO Pandemic Agreement;
and
(e) consider other action, as appropriate, for the achievement of the objective of the WHO
Pandemic Agreement in the light of experience gained in its implementation.
8. The Conference of the Parties shall keep under regular review, every three years, the
implementation and outcome of the WHO Pandemic Agreement and any related legal instruments that
the Conference of the Parties may adopt, and shall make the decisions necessary to promote the effective
implementation of the WHO Pandemic Agreement.
9. The Conference of the Parties shall establish subsidiary bodies to carry out the work of the
Conference of the Parties, as it deems necessary, on terms and modalities to be defined by the
Conference of the Parties. Such subsidiary bodies may include, without limitation, an Implementation
and Compliance Committee, a panel of experts to provide scientific advice and a WHO PABS System
Expert Advisory Group.
A/INB/7/3
26
Article 22. Right to vote
1. Each Party to the WHO Pandemic Agreement shall have one vote in the Conference of the Parties,
except as provided for in paragraph 2 of this Article.
2. Regional economic integration organizations, in matters within their competence, shall exercise
their right to vote with a number of votes equal to the number of their Member States that are Parties to
the WHO Pandemic Agreement, duly accredited and present during the voting. Such an organization
shall not exercise its right to vote if any of its Member States exercises its right, and vice versa.
Article 23. Reports to the Conference of the Parties
1. Each Party shall submit to the Conference of the Parties periodic reports on its implementation of
the WHO Pandemic Agreement, which shall include the following:
(a) information on good practices, legislative, executive, administrative or other measures
taken to implement the WHO Pandemic Agreement;
(b) information on any constraints or difficulties encountered in the implementation of the
WHO Pandemic Agreement and on the measures taken or under consideration to overcome them;
(c) information on implementation support received under the WHO Pandemic Agreement;
and
(d) other information as required by specific provisions of the WHO Pandemic Agreement.
2. The frequency, conditions and format of the reports, including periodic reports, submitted by the
Parties shall be determined by the Conference of the Parties at its first session, with the aim of facilitating
reporting by the Parties and avoiding duplications. These reports shall be drawn up in a clear, transparent
and exhaustive manner, without prejudice to respect for applicable rules on confidentiality, privacy and
data protection.
3. The Conference of the Parties shall adopt appropriate measures to assist Parties, upon request, in
meeting their obligations under this Article, paying particular attention to the needs of developing
country Parties.
4. The periodic reports submitted by the Parties shall be made publicly available online by the
Secretariat.
Article 24. Secretariat
1. A Secretariat for the WHO Pandemic Agreement is hereby established. Secretariat functions for
the WHO Pandemic Agreement shall be provided by the World Health Organization.
2. Secretariat functions shall be to:
(a) provide administrative and logistic support to the Conference of the Parties for the purpose
of the implementation of this Agreement, and to make arrangements for the sessions of the
Conference of the Parties and any subsidiary bodies and to provide them with services, as
required;
A/INB/7/3
27
(b) transmit reports and other relevant information regarding the implementation of this
Agreement received by it pursuant to this Agreement;
(c) provide support to the Parties, upon request, particularly developing country Parties and
Parties with economies in transition, in implementing the WHO Pandemic Agreement, including
the compilation and communication of information required in accordance with the provisions of
the WHO Pandemic Agreement or pursuant to requests of the Conference of the Parties;
(d) prepare reports on its activities under the WHO Pandemic Agreement under the guidance
of the Conference of the Parties, and to submit them to the Conference of the Parties;
(e) ensure, under the guidance of the Conference of the Parties, the necessary coordination
with competent international and regional intergovernmental organizations and other bodies;
(f) enter, under the guidance of the Conference of the Parties, into such administrative or
contractual arrangements as may be required for the effective discharge of its functions;
(g) cooperate and coordinate with other United Nations entities in related areas; and
(h) perform other secretariat functions specified by the WHO Pandemic Agreement and such
other functions as may be determined by the Conference of the Parties.
Article 25. Relationship with other international agreements and instruments
1. The implementation of the WHO Pandemic Agreement shall be guided by the Charter of the
United Nations and the Constitution of the World Health Organization.
2. The Parties recognize that the WHO Pandemic Agreement and other relevant international
instruments, including the International Health Regulations, should be interpreted so as to be
complementary and compatible. The provisions of the WHO Pandemic Agreement shall not affect the
rights and obligations of any Party under other existing international instruments.
3. The provisions of the WHO Pandemic Agreement shall in no way affect the ability of Parties to
enter into bilateral or multilateral agreements, including regional or subregional agreements, on issues
relevant or additional to the WHO Pandemic Agreement, provided that such agreements are compatible
with their obligations under the WHO Pandemic Agreement. The Parties concerned shall communicate
such agreements to the Conference of the Parties, through the Secretariat.
Article 26. Reservations
No reservations may be made to the WHO Pandemic Agreement.
Article 27. Withdrawal
1. At any time after two years from the date on which the WHO Pandemic Agreement has entered
into force for a Party, that Party may withdraw from the WHO Pandemic Agreement by giving written
notification to the Depositary.
2. Any such withdrawal shall take effect upon expiry of one year from the date of receipt by the
Depositary of the notification of withdrawal, or on such later date as may be specified in the notification
of withdrawal.
A/INB/7/3
28
3. Any Party that withdraws from the WHO Pandemic Agreement shall not be considered as having
also withdrawn from any protocol to which it is a Party, or from any related instrument, unless such a
Party formally withdraws from such other instruments and does so in accordance with the relevant terms,
if any, thereof.
Article 28. Amendments
1. Any Party may propose amendments to the WHO Pandemic Agreement. Such amendments shall
be considered by the Conference of the Parties.
2. Amendments to the WHO Pandemic Agreement shall be adopted by the Conference of the Parties.
The text of any proposed amendment to the WHO Pandemic Agreement shall be communicated to the
Parties by the Secretariat at least six months before the session at which it is proposed for adoption. The
Secretariat shall also communicate proposed amendments to the signatories of the WHO Pandemic
Agreement and, for information, to the Depositary.
3. The Parties shall make every effort to adopt any proposed amendment to the WHO Pandemic
Agreement by consensus. If all efforts at consensus have been exhausted and no agreement has been
reached, the amendment shall as a last resort be adopted by a three-quarters majority vote of the Parties
present and voting at the session. For the purposes of this Article, Parties present and voting means
Parties present and casting an affirmative or negative vote. Any adopted amendment shall be
communicated by the Secretariat to the Depositary, who shall circulate it to all Parties for acceptance.
4. Instruments of acceptance in respect of an amendment shall be deposited with the Depositary. An
amendment adopted in accordance with paragraph 3 of this Article shall enter into force, for those Parties
having accepted it, on the ninetieth day after the date of receipt by the Depositary of an instrument of
acceptance by at least two thirds of the Parties to the WHO Pandemic Agreement.
5. The amendment shall enter into force for any other Party on the ninetieth day after the date on
which that Party deposits with the Depositary its instrument of acceptance of the said amendment.
Article 29. Annexes
1. Annexes to the WHO Pandemic Agreement and amendments thereto shall be proposed, adopted
and shall enter into force in accordance with the procedure set forth in Article 28 herein.
2. Annexes to the WHO Pandemic Agreement shall form an integral part thereof and, unless
otherwise expressly provided, a reference to the WHO Pandemic Agreement constitutes at the same
time a reference to any annexes thereto.
3. Annexes shall be restricted to lists, forms and any other descriptive material relating to procedural,
scientific, technical or administrative matters, and shall not be substantive in nature.
Article 30. Protocols
1. Any Party may propose protocols to the WHO Pandemic Agreement. Such proposals will be
considered by the Conference of the Parties.
A/INB/7/3
29
2. The Conference of the Parties may adopt protocols to the WHO Pandemic Agreement. In adopting
these protocols, every effort shall be made to reach consensus. If all efforts at consensus have been
exhausted and no agreement has been reached, the protocol shall as a last resort be adopted by a
three-quarters majority vote of the Parties present and voting at the session. For the purposes of this
Article, Parties present and voting means Parties present and casting an affirmative or negative vote. In
the event that a protocol is proposed for adoption under Article 21 of the Constitution of the World
Health Organization, it shall further be considered for adoption by the Health Assembly.
3. The text of any proposed protocol shall be communicated to the Parties by the Secretariat at least
six months before the session at which it is proposed for adoption.
4. States that are not Parties to the WHO Pandemic Agreement may be parties to a protocol thereof,
provided the protocol so provides.
5. Any protocol to the WHO Pandemic Agreement shall be binding only on the parties to the
protocol in question. Only parties to a protocol may take decisions on matters exclusively relating to the
protocol in question.
6. The requirements for entry into force of any protocol shall be established by that instrument.
Article 31. Signature
The WHO Pandemic Agreement shall be open for signature by all Members of the World Health
Organization, by States that are not Members of the World Health Organization but are member or
non-member observer states of the United Nations, and by regional economic integration organizations.
The WHO Pandemic Agreement shall be open for signature at the World Health Organization
headquarters in Geneva, immediately following its adoption by the World Health Assembly at the
Seventy-seventh World Health Assembly, from XX [May] 2024 to XX [June] 2024, and thereafter at
United Nations Headquarters in New York, from XX [June] 2024 to XX [June] 2025.
Article 32. Ratification, acceptance, approval, formal confirmation or accession
1. The WHO Pandemic Agreement shall be subject to ratification, acceptance, approval or accession
by States and to formal confirmation or accession by regional economic integration organizations. The
WHO Pandemic Agreement shall be open for accession from the day after the date on which the WHO
Pandemic Agreement is closed for signature. Instruments of ratification, acceptance, approval, formal
confirmation or accession shall be deposited with the Depositary.
2. Any regional economic integration organization that becomes a Party to the WHO Pandemic
Agreement without any of its Member States being a Party shall be bound by all the obligations under
the WHO Pandemic Agreement. In the case of those regional economic integration organizations for
which one or more of its Member States is a Party to the WHO Pandemic Agreement, the regional
economic integration organization and its Member States shall decide on their respective responsibilities
for the performance of their obligations under the WHO Pandemic Agreement. In such cases, the
regional economic integration organization and its Member States shall not be entitled to exercise rights
under the WHO Pandemic Agreement concurrently.
3. Regional economic integration organizations shall, in their instruments relating to formal
confirmation or in their instruments of accession, declare the extent of their competence with respect to
the matters governed by the WHO Pandemic Agreement. These organizations shall also inform the
Depositary, who shall in turn inform the Parties, of any substantial modification in the extent of their
competence.
A/INB/7/3
30
Article 33. Entry into force
1. The WHO Pandemic Agreement shall enter into force on the thirtieth day following the date of
deposit of the fortieth instrument of ratification, acceptance, approval, formal confirmation or accession
with the Depositary.
2. For each State that ratifies, accepts or approves the WHO Pandemic Agreement or accedes thereto
after the conditions set forth in paragraph 1 of this Article for entry into force have been fulfilled, the
WHO Pandemic Agreement shall enter into force on the thirtieth day following the date of deposit of its
instrument of ratification, acceptance, approval or accession.
3. For each regional economic integration organization depositing an instrument of formal
confirmation or an instrument of accession after the conditions set forth in paragraph 1 of this Article
for entry into force have been fulfilled, the WHO Pandemic Agreement shall enter into force on the
thirtieth day following the date of deposit of its instrument of formal confirmation or of accession.
4. For the purposes of this Article, any instrument deposited by a regional economic integration
organization shall not be counted as additional to those deposited by Member States of that regional
economic integration organization.
Article 34. Settlement of disputes
1. In the event of a dispute between two or more Parties concerning the interpretation or application
of the WHO Pandemic Agreement, the Parties concerned shall seek through diplomatic channels a
settlement of the dispute through negotiation or any other peaceful means of their own choice, including
good offices, mediation or conciliation. Failure to reach a solution by good offices, mediation or
conciliation shall not absolve the parties to the dispute from the responsibility of continuing to seek to
resolve it.
2. When ratifying, accepting, approving, formally confirming or acceding to the WHO Pandemic
Agreement, or at any time thereafter, a Party which is not a regional economic integration organization
may declare in writing to the Depositary that, for a dispute not resolved in accordance with paragraph 1
of this Article, it accepts, as compulsory ipso facto and without special agreement, in relation to any
Party accepting the same obligation: (a) submission of the dispute to the International Court of Justice;
and/or (b) ad hoc arbitration in accordance with procedures to be adopted by consensus by the
Conference of the Parties. A Party which is a regional economic integration organization may make a
declaration with like effect in relation to arbitration in accordance with the procedures referred to in
paragraph 2(b) of this Article.
3. The provisions of this Article shall apply with respect to any protocol as between the parties to
the protocol, unless otherwise provided therein.
Article 35. Depositary
The Secretary-General of the United Nations shall be the Depositary of this Agreement and
amendments thereto and of any protocols and annexes adopted in accordance with the terms of this
Agreement.
Article 36. Authentic texts
The original of this Agreement, of which the Arabic, Chinese, English, French, Russian and
Spanish texts are equally authentic, shall be deposited with the Secretary-General of the United Nations.
= = =

パンデミックの予防、備え、対応に関するWHO条約、 協定、またはその他の国際 文書の起草と交渉を目的とした政府間
交渉機関の第9回会合が再開 A/INB/9/3 Rev.1 暫定議題項目2 2024年4月22日 WHOパンデミックに対する提案契約 A/INB/9/3 Rev.1

2
目次
第 1 章. はじめに …………………………………………………………………………………………………….. 5
第 1 条. 利用について用語…………………………………………………………………………………………。 5
第 2 条. 目的 ………………………………………………………………………………………………… 6
第 3 条. 原則 … …………………………………………………………………………………………………… 6
第Ⅱ章世界は公平に共に: パンデミックの
予防、準備、対応における、そのための、そしてそれを通じて公平性を達成する ………………………………………………………………….. 7
第 4 条. パンデミックの予防と対応公衆衛生監視………………………………………….. 7
第 5 条. One Health ……………………………………………………………… ……………………………………………… 8
第 6 条。準備、即応性、医療システムの回復力………………………………………………。 8
第 7 条. 医療およびケアの労働力 ………………………………………………………………………… 9
第 8 条. 準備状況のモニタリングと機能レビュー ………… ………………………………………………… 10
第9条 研究開発 ………………………………………………………………… …。 10
第 10 条. 持続的かつ地理的に多様な生産、技術
移転およびノウハウ………………………………………………………………………………。 10第 11 条 パンデミック関連の 健康製品
製造のための技術およびノウハウの移転…………………………………………………………………………
…………。 11
第 12 条。アクセスと利益の共有……………………………………………………………………。 12
第 13 条。サプライチェーンおよび物流………………………………………………………………………….. 14
第 13 条の 2。国家調達と流通…………………………………………………………。 14
第 14 条 規制の強化 ……………………………………………………………………………… 15
第 15 条 補償および責任の管理 ……………… ……………………………………………………… 16
第 16 条 国際連携及び協力 ……………………………………………………………… 16
第 17 条政府全体および社会全体のアプローチ…………………………………….. 16
第 18 条. コミュニケーションと国民の意識………………………………………… ……………………。 16
第 19 条. 国際協力と実施支援 ………………………………………… 17
第 20 条. 持続可能な資金調達 …………………………………………………… …………………………… 17
第Ⅲ章．制度上の取り決めと最終規定……………………………………………….. 18
第 21 条 締約国会議……………………………………………… …………………………………………… 18
第 22 条 投票権 ……………………………………………………………………… ……………….. 19
第 23 条 締約国会議への報告…………………………………………………………。 19
第 24 条. 事務局……………………………………………………………………………………………… 19
第 25 条. 紛争の解決…… ………………………………………………………………………….. 20
第 26 条 他の国際協定および国際文書との関係 ……………… …… 20
第 27 条 予約………………………………………………………………………………………….. 20
A/INB/ 9/3 Rev.1

3
第 28 条. 宣言および陳述 ………………………………………………………………………………20
第 29 条. 修正 ………………………… ………………………………………………………………..20
第 30 条 附属書……………………………………………… ………………………………………………………………21
第 31 条 プロトコル ………………………………………………………… ………………………………………..21
第 32 条 退会…………………………………………………………………… …………………………..21
第 33 条 署名 ……………………………………………………………………………… ……………..22
第 34 条. 批准、受諾、承認、正式な確認または加入 ………………..22
第 35 条. 発効 ………………………………… ………………………………………………….23
第 36 条 寄託者 …………………………………………………………… ………………………………………………23
第 37 条 正文…………………………………………………………………… ………………..23
A/INB/9/3 Rev.1

4
WHO パンデミック協定の締約国、 1. 国家は 国民の
健康と福祉を支援する主な責任を負い、国家はパンデミックの予防、備え 、対応を強化する基礎であることを認識し、 2.締約国の発展のレベルによって、 パンデミックの予防、備え、対応において異なる能力や能力が生み出され 、健康増進と疾病、特に伝染病の管理における発展の不平等は 、国際協力による支援を必要とする共通の危険であることを認識する。 より大きな能力と資源、ならびに予測可能で 持続可能かつ十分な財政的、人的、物流的、技術的および技術的資源を有する国々の支援を含む。 3. 世界保健機関が国際的な保健活動の指揮および調整機関であることを認識し 、パンデミックの予防、備え、対応を含む。 4. 達成可能な最高水準の健康を享受することは、 人種、宗教、政治的区別 なくすべての人間の基本的権利の 1 つである と述べている世界保健機関憲法を想起する。 5. 1979 年 12 月 18 日に国連総会で採択された 女性に対するあらゆる形態の差別撤廃条約が、同条約の締約国が差別を撤廃するために適切な措置を講じなければならないと規定し ていることを想起し、 医療分野における女性に対する差別、および持続可能な開発目標 5 が「男女平等を達成し、 すべての女性と女児に力を与える」ことを目指していること、 6. 病気の国際的な蔓延が 生命、生活、効果的、 協調的、適切かつ包括的な社会 を確保するために、 すべての人々と国、特に発展途上国、とりわけ後発開発途上国と小島嶼開発途上国との可能な限り広範な国際的および地域的な協力、協力、連帯を求める社会と経済。 公衆衛生問題に対処する際の国家主権の原則を再確認しつつ、公平な国際的対応を行い、

7.コロナウイルス感染症（COVID-19）パンデミック関連の健康製品への 適時かつ公平なアクセスを妨げる国内および国際レベルでの不平等、および
パンデミックの予防、準備、対応における重大な欠陥に深く懸念し、
8. 重要な役割を認識する。パンデミックの予防、 準備、対応、保健システムの 強化における先住民族の文化と知識の
価値と多様性をさらに認識し、広範な社会参加を通じて、国家レベルおよび地域社会レベルで政府全体および社会全体のアプローチを強化する。 9.パンデミックの予防、準備、対応、医療システムの 回復 のための分野を超えた協力を通じて、政治的コミットメント、資源、行動を確保することの重要性を認識する。 10. 人類を守るための国、地域、国際 レベルでの多分野協力の重要性を再確認する。 One Health アプローチを含む健康、 A/INB/9/3 Rev.1

5 11. 国際人権法および国際人道法を含む国際法に従って、人道援助へ
の迅速かつ妨げのないアクセスの重要性と、 人道援助の 提供における人道、中立、公平および独立の原則の尊重を認識する。 , 12.パンデミックに対応し、特にプライマリ・ヘルスケアの アプローチを通じてユニバーサル・ヘルス・カバレッジの達成を推進するために、 適切な数の熟練し、訓練を受け、保護された医療・介護従事者を配置し、 強靱な医療システムの構築と強化に取り組む必要性を改めて表明する。 ;パンデミックが 医療サービスへのアクセスにおける既存の不平等を悪化させるリスクを軽減するための公平なアプローチを採用すること、 13. 信頼を構築し、誤った情報、偽情報、偏見を防ぐために情報をタイムリーに共有することの重要性を認識すること 、 14. 知的財産の重要性を認識すること財産保護は新薬の開発にとって重要であり 、その価格への影響に関する懸念を認識し、知的財産権の貿易関連側面に関する協定（TRIPS協定）は 加盟国の措置を妨げる ものではないし、妨げるべきではないことを想起する。公衆衛生を保護するため。 15. 生物資源に対する国家の主権と公衆衛生上のリスクを軽減するための集団的行動の重要性を想起し、 資料と情報の適時、安全、透明性、責任ある迅速な共有を 促進することの重要性を強調する。 16. 公衆衛生上の目的でパンデミックの可能性がある病原体について、また、関連する国内法、国内法、国際 法 を考慮して、 対等な立場で、そこから生じる利益をタイムリーかつ公正かつ公平に分配すること。 16. パンデミックの適切な予防と備えを強調する、対応および医療システムの回復は 、他の健康上の緊急事態と闘い、 健康の社会的、環境的、文化的、政治的、経済的決定要因に対する断固たる行動を通じてより大きな健康の公平性を達成するための継続体の一部であり、 17. 健康の重要性と公衆衛生への影響を認識する。気候変動、 貧困と飢餓、脆弱で脆弱な環境、脆弱な一次医療、 抗菌薬耐性の蔓延など、増大する脅威、

第 I章 はじめに
第 1 条 用語の使用
WHO パンデミック協定の目的: (a) 「製造業者」と は、パンデミック関連の健康製品
を開発および/または生産する公的または民間の事業体を意味します。 (b) 「One Health アプローチ」 とは、人、動物、生態系の健康のバランスを 持続的に最適化し、最適化することを目的とした統合的かつ統一的なアプローチを意味します。 人間、家畜および野生動物、植物、およびより広範な環境（生態系を含む）の健康は 密接に関連しており、相互依存していることを認識しています。 A/INB/9/3 Rev.1

6
(c) 「PABS 材料および情報」とは、パンデミックの可能性がある病原体からの生物学的材料
、および
パンデミック関連の健康製品の開発に関連する配列情報を意味します。
(d) 「パンデミック関連の健康製品」とは、パンデミックの予防、備え、対応に必要な安全、効果的、高品質かつ手頃な価格の製品を意味し、これに は診断薬、治療薬、ワクチン、個人用保護具が
含まれますが、これらに限定されません。 (e) 「締約国」とは 、条件に従って本協定に拘束されることに同意し、本協定が有効である 国家 または地域の経済統合組織を意味します。 (f) 「パンデミックの可能性のある病原体」とは、ヒトに感染することが確認されており、新規（まだ特徴付けられていない）または既知（既知の 病原体の変異体を含む）で、潜在的に伝播性が高い、および/または毒性が高い、 あらゆる病原体を意味します。 国際的に懸念される公衆衛生上の緊急事態を引き起こす可能性がある。 (g) 「脆弱な状況にある人」とは、パンデミック の状況下で、感染、重症度、疾病または死亡のリスクが不釣り合いに増加している 個人、集団、またはコミュニティを意味します 。これには、脆弱で人道的な状況にある人々が含まれると理解されています。 (h) 「地域経済統合機関」 とは、複数の主権国家で構成され、その加盟国がさまざまな事項に関する権限を移転した 組織を意味します。これには、 当該事項 に関して加盟国を拘束する決定を下す権限も含まれます。;1 および (i) 「国民皆保険」とは、すべての人々が 、必要なときに、必要な場所で、経済的困難を伴うことなく、必要なあらゆる種類の質の高い医療サービスにアクセスできることを意味します。健康増進から予防、治療、 リハビリテーション、緩和ケア に至るまで、一連の必須の医療サービスを網羅しています。 第 2 条. 目的 1. WHO パンデミック協定の目的は、公平性とここでさらに規定される原則に基づいて 、パンデミックを予防し、準備し、対応することです。 2. この目的を推進するために、別段の定めがない限り、WHO パンデミック協定の規定は パンデミック中およびパンデミック間の両方に適用されます。 第3条 原則

WHO パンデミック協定の目的を達成し、その規定を実施するために、
締約国は、特に以下の指針に従うものとする。 1. 各国の管轄区域内で、以下 の規定に従って
法律を採択し、立法し、実施する主権的権利
国連憲章、WHO憲法、
国際法の原則、生物資源に対する主権的権利。
1 必要に応じて、「国家」は地域経済統合組織を同様に指します。
A/INB/9/3 Rev.1

7
2. すべての人の尊厳、人権および基本的自由を完全に尊重し、
すべての人間が達成可能な最高水準の健康を享受すること。 3. パンデミックの効果的な予防、準備 、対応の
ための国際人道法を完全に尊重する。 4. パンデミックの予防、準備、対応の目標および結果としての公平性。個人、コミュニティ 、国家 間の不公平、回避可能または是正可能な差異がないように努める。 5. さまざまなレベルの能力と 能力 を認識し、パンデミックを予防し、対応し、回復するための より公平でよりよく準備された世界の共通の利益を達成するため の、健康上の緊急事態の文脈におけるすべての人々および国との連帯、包括性、透明性、説明責任; 6. パンデミックの予防、準備、対応のための公衆衛生上の決定の基礎として利用可能な最良の科学と証拠 。 第 2 章世界は公平に共に: パンデミックの予防、準備と対応における、そのための、そしてそれを通じての公平性の達成 第 4 条 パンデミックの予防と公衆衛生監視1. 締約国は、 パンデミックの予防を段階的に強化する ために、二国間、地域、多国間の状況で相互に協力するものとする。国際保健規則（2005 年）に準拠し、国および地域の 状況 を考慮した公衆衛生監視能力。 2. 各締約国は、 国際保健規則（2005 年）の効果的な実施と一致し、その効果的な実施を支援する、また 自国の能力に従って、包括的な 多分野にわたる国家的パンデミック予防および公衆衛生監視計画を開発、強化、実施し、定期的に更新し、見直すものとする。そしてそれは、特に以下をカバーする： (a) 共同監視。 (b) コミュニティベースの早期発見および制御措置。 (c) 水、衛生設備、衛生。 (d) 定期予防接種。 (e) 感染の予防と管理。 (f) 人獣共通感染症の流出および流出の防止。 (g) 病原体への偶発的な暴露、誤用、または不用意な放出を 防止するための実験室の生物学的リスク管理。

(h) ベクター媒介疾患の監視と予防。および
A/INB/9/3 Rev.1

8 (i) 抗菌剤に耐性のある病原体の出現と蔓延
に関連するパンデミック関連のリスクに対処するための抗菌剤耐性。 3. 締約国は、環境、気候、社会、人為的、経済的要因がパンデミックのリスクを増大させることを認識し、これらの要因を特定するよう努め、国際的、 地域的、国際的な 分野における関連する政策、戦略、措置の開発と実施において それらを考慮に入れる。他の関連する 国際文書とその実施との相乗効果を強化するなど、必要に応じて国家レベルでの対応を強化する。 4. 締約国会議は、必要に応じて、 本条の実施を支援するために、パンデミック防止能力に関連したものを含むガイドライン、勧告および基準を採択することができる 。 第 5 条. One Health 1. 締約国は、パンデミックの予防、備え 、対応のため、人間、動物、環境の間の相互関係を認識し、関連 するすべての組織、分野の間で一貫性があり、統合され、調整され、協力する One Health アプローチを推進することを約束する。 国家事情を考慮して、俳優も含めて。 2. 締約国は、関連するパンデミックの予防、準備、対応計画への介入の 導入と統合を通じて、パンデミックの推進要因と、人間と動物と環境の接点における病気の出現と再発を特定し 、対処することを約束する。 3. 各締約国は、自国の状況に応じて、 WHO およびその他の関連国際機関の支援を得て、以下のことにより、人間、動物、および植物の健康を保護するものとする。 (a) ワンヘルス を反映する関連する国家政策および戦略を実施し、定期的に見直す。パンデミックの予防、準備、対応に関連するアプローチ。 (b) 流行 を予防、発見、対応するための政策、戦略、対策の 開発と実施における地域社会の効果的かつ有意義な関与を促進する。 (c) 関連性のある補完的な スキル、能力、および能力を構築するための、人間、動物、および環境保健従事者向けの One Health 共同トレーニングおよび継続教育プログラムを促進または 確立する。

4. One Health アプローチのモダリティ、契約条件および運用上の側面は、
国際保健規則 (2005 年) の規定を考慮した文書でさらに定義され
、2026 年 5 月 31 日までに運用される予定である。
第 6 条 準備状況、即応性および医療システムのレジリエンス
1. 各締約国は、ユニバーサル・ヘルスの達成を目指し、公平性の
必要性を考慮しつつ
、パンデミックの予防、準備および対応のためのレジリエントな医療システム、特にプライマリ・ヘルスケアを開発、強化、維持することを約束する。カバレッジ。
2. 各締約国は、必要に応じて自国の国内法および/または国内法およびその能力に従って、 政策、計画、戦略の採用および/または開発を含め、
医療システムの機能およびインフラストラクチャーの開発または強化、維持および監視に取り組むことを約束する。
および必要に応じて次の措置を講じます:
A/INB/9/3 Rev.1

9
(a) プライマリ
ヘルスケア、メンタルヘルス、心理社会的サポートに重点を置き、弱い立場にある人々に特に配慮しながら、パンデミック時の拡張可能な臨床ケア、質の高い日常的および必須のヘルスケアサービスをタイムリーに提供し、
公平にアクセスすること。 ;
(b) パンデミック後の医療システムの回復。 (c) 検査室のバイオセーフティーおよび バイオセキュリティー に関する関連基準およびプロトコルの適用を通じた、
検査室および診断能力、ならびに関連する国内、地域および世界規模のネットワーク。 (d) パンデミックの予防、備え、対応のための 社会科学および行動科学の利用、リスクコミュニケーション、地域社会の関与を促進する。 3. 締約国は、WHO および関連する国際機関と協力し、必要に応じて国内法および/または国内法に従い、 タイムリーな共有を可能にする関連する国際データ標準および相互運用性を 特定、推進および/または強化するよう努めるものとする。 公衆衛生事象の予防、検出、対応のための公衆衛生データの収集。 4. 締約国間の学習、ベストプラクティス、説明責任とリソースの調整を促進および支援する目的で 、包括的、透明性、効果的かつ効率的なパンデミックの予防、準備および対応の監視および評価システムが開発、 実施され、定期的に評価される ものとする。 WHOは 、締約国会議で合意される予定のスケジュールに基づいて、関連組織と協力し、関連ツールに基づいて作成します。 第 7 条 医療および介護労働力 1. 各締約国は、それぞれの能力および国内事情に応じて、次のような問題を防止するため 、学際的で熟練した訓練を受けた多様な労働力を確立、保護、保護、投資および維持するために必要な措置を講じるものとする 。 パンデミック下でも 質の高い不可欠な医療サービスと不可欠な公衆衛生機能を維持しながら、人道的状況を含む健康上の緊急事態の発生源に最も近いところで備え、対応する。 2. 各締約国は、パンデミック中にパンデミック関連の健康製品への優先アクセスを確保することなどにより、自国の医療・介護従事者の継続的な安全、福祉 、能力を保護し確保するための適切な措置を講じ 、それによって医薬品の供給の中断を最小限に抑えるものとする。品質

不可欠な医療サービス。
3. 締約国は、公衆衛生上のニーズに基づいて、要請に応じて締約国を支援するために配置可能な、熟練し、訓練を受け、調整された
学際的な世界保健緊急要員の確立と維持に投資し、
発生を封じ込め、小規模な感染拡大が世界
規模に拡大するのを防ぐものとする。 。
4. 締約国は、必要に応じて、船員や国境を越えた輸送労働者など、パンデミック時に重要なサプライチェーン
の正常な機能に不可欠な労働者の安全と保護のための調整された政策と
措置を策定し、実施することを約束するものとする。必要に応じて、
移動や移動を容易にし、医療へのアクセスを確保することもできます。
5. 締約国は、適用される国際規定および基準を考慮し、医療従事者の移動の自由
を尊重しつつ、医療従事者の移動が医療制度に及ぼす悪影響を最小限に抑えるために
、多国間および二国間メカニズムを通じて必要に応じて協力するものとする
。
A/INB/9/3 Rev.1

10
第 8 条 準備状況の監視と機能のレビュー ?この条の規定は
第 6 条に移動された（番号付けの目的のみに保持）
第 9 条 研究開発1. 締約国は 、特に開発途上国における研究開発のための
地理的に多様な能力および機関を構築、強化および維持するために協力するものとする。 特にパンデミック時に情報と結果を迅速に共有するために、オープンサイエンスのアプローチ
を通じて
研究協力と研究へのアクセスを促進するものとします。 2. この目的のために、締約国は、自由に使える手段と資源の範囲内で、以下を推進するものとする。 (a) 公衆衛生の優先事項のための研究開発への持続的な投資。 (b) 開発途上国の科学者および/または研究センター の参加を積極的に関与させる、技術の共同創造および合弁事業の取り組み。 (c) 能力開発プログラム、プロジェクトおよびパートナーシップ、ならびに 基礎研究および応用研究を含む研究開発のあらゆる段階に対する実質的かつ継続的な支援。 (d) 革新的な研究開発を加速するため、 適用されるバイオセーフティーおよびバイオセキュリティー義務、法律、規制およびガイダンスに従って、関連する利害関係者の参加 。 3. 締約国は、各国の状況に従い、関連する国際 基準と義務を念頭​​に置き、 臨床試験の能力 を開発、強化、維持することにより、適切に設計され適切に実施された臨床試験を支援するための国際的な調整と協力を強化するための措置を講じるものとする。国、地域、国際レベルでの研究ネットワークを構築し、 そのような試験からのデータの迅速な報告と解釈を促進します。 4. 各締約国は 、パンデミック関連の健康製品の開発 のための政府資金による研究開発契約に、必要に応じて 、かかる製品への適時かつ公平なアクセスを促進する条項が含まれていることを確保し、関連条件を公表するものとする。このような規定 には以下が含まれる場合があります。(i) ライセンスおよび/またはサブライセンス（できれば非独占的ベース）。 (ii) 手頃な価格設定 ポリシー。 (iii) 相互に合意した条件に基づく技術移転。 (iv) 関連情報の公表

研究のインプットとアウトプット。および/または (v) WHO が採用した製品割り当て枠組みの遵守。
第 10 条 持続可能かつ地理的に多様な生産、技術
移転とノウハウ
1. 締約国は、パンデミック関連の健康製品のより公平な地理的分布と世界生産の拡大を達成し、持続可能でタイムリーで公正かつ 公平なアクセスを
増加させることにコミットする。 相互に合意した条件に基づいて関連技術とノウハウを移転することで、パンデミック時の
潜在的な需要と供給のギャップを縮小するだけでなく、そのような製品への提供も可能です。 2. 締約国は、WHO およびその他の関連組織と協力して、以下 を行うものとする。 (a) 必要に応じて、 国および地域レベル、特に発展途上国の施設、および A/INB/9/3 Rev.1 の促進を目的として、パンデミックの可能性がある病原体に関連する疾病負荷研究を実施しました。

11関連する パンデミック関連の健康製品
の生産または生産の拡大のための、そのような投資の持続可能性。 (b) パンデミック関連製品の生産を拡大するために、必要に応じて国内法および/または国内法、および 本条第 2 項(a) で言及されている製造業者以外の製造業者を特定し契約するための規制に従って、措置を講じる。パンデミック中、生産施設の生産および供給能力 が需要を満たさない 場合の健康製品。 (c) パンデミック関連の健康製品の 戦略的かつ地理的に分散した生産を促進するために、適切な WHO の関連技術、スキル、ノウハウ移転プログラムを 積極的に支援、参加、および/または実施する。 (d) パンデミック関連の健康製品の製造施設または生産能力、特に開発途上国に拠点を置く地域的な運営範囲を持つ施設の創設または拡大を目的とした官民セクターの投資および /またはパートナーシップを促進および奨励 する。第 11 条 パンデミック関連健康製品 の生産のための技術およびノウハウの移転 1. 各締約国は、パンデミック関連健康製品の十分かつ持続可能かつ地理的に多様な生産を可能にするために 、自国の国家的利益を考慮しなければならない。状況: (a) パンデミック関連の健康製品の技術およびノウハウの移転を促進し、その他の方法で促進または奨励する。 特に発展途上国の利益のために、また その開発に公的資金を受けている技術については、さまざまな手段を通じて行う。 相互に合意した条件に基づくライセンス供与などの措置。 (b) パンデミック関連の医療技術のライセンス条項を適時に 、適用法に従って公表し、私権所有者にも 同様のことを奨励するものとする。 (c) 研究開発機関や製造業者、特に 多額の公的融資を受けている企業に対し、パンデミック関連の健康製品の製造に自社の技術を使用する際のロイヤルティを一定期間見合わせたり減額したりすることを奨励する 。 (d) パンデミック関連の関連技術および関連ノウハウの移転を促進する。

私権所有者による健康製品は、
譲歩条件や優先条件を含む公正かつ最も有利な条件で、相互に合意された契約条件に従って、
確立された地域または世界的な技術移転ハブ、またはその他の多国間メカニズムや
ネットワークに提供されるほか、出版物も提供されます。かかる契約の条件について。
(e) 公的資金を受けた関連特許の保有者、および
必要に応じてパンデミック関連の健康製品に関する他の関連特許の保有者に対し、
ロイヤルティを放棄するか、開発途上国の製造業者に妥当なロイヤルティで関連特許をライセンス供与するよう奨励する
。パンデミック中、
パンデミック関連の健康製品を製造するための技術とノウハウ。 (f) A/INB/9/3 Rev.1 が施行された場合
、管轄区域内の製造業者に対し、パンデミック中にパンデミック関連の健康製品の製造に関連する情報を適切に共有するよう奨励する
。

12そのような情報が保留されると 、パンデミックへの対応に必要な医薬品
の緊急製造が妨げられ、または妨げられます。 2. 各締約国は、その能力の範囲内で、利用可能なリソースと適用法に従って 、パンデミック関連の健康製品の技術とノウハウを 相互に合意した条件で、特に地方、準地域、および地域に移転するための能力構築の支援を提供するものとする。 /または 発展途上国に拠点を置く地域メーカー。 3. パンデミック時の手頃な価格のパンデミック関連健康製品の入手可能性と適切性を高めるために必要な範囲で、関連組織の枠組みの中で、パンデミック関連健康 製品の製造を加速または拡大するための適切な措置を支援することを 検討する。 4. 世界貿易機関（WTO）加盟国は、 2001 年の TRIPS 協定と公衆衛生に関する ドーハ宣言で再確認されたものを含め、TRIPS 協定の柔軟性を最大限に活用する権利を有することを再確認する。これは、将来のパンデミックにおいて公衆衛生を保護するための柔軟性を提供し、 WTO加盟国による TRIPS協定の柔軟性の利用を完全に尊重するものとする。 5. 締約国は、締約国会議を通じて、 パンデミック関連製品の生産のための技術と ノウハウの移転を増加し、地理的に多様化するために、WHOが調整する地域的または世界的な技術とノウハウの移転拠点を設立するものとする。 発展途上国のメーカーによる健康製品。 第 12 条 アクセスと利益の共有 1. パンデミックの可能性がある病原体に対する多国間アクセスと利益の共有システムである WHO病原体アクセスと利益の共有システム (PABS システム) が、迅速、 体系的かつタイムリーな共有を 確保するためにここに確立されるとりわけ公衆衛生リスク評価のための PABS の資料と情報の提供、および そのような共有 から生じるパンデミック関連の健康製品やその他の金銭的および非金銭的利益 への平等な立場でのタイムリーで効果的、予測可能かつ公平なアクセス。 PABS システムは WHO によって調整され、招集されます。 2. PABS システムは以下の基盤を有するものとする: (a) PABS 資料および情報を平等な立場で共有するという締約国の約束

およびそこから生じる利益。これらは
世界の公衆衛生に対する共同行動の同様に重要な部分であると考えられます。 (b) 研究と イノベーション
を強化、促進し、抑制しない方法での実施。 (c) パンデミック インフルエンザ対策フレームワーク との相互補完性を確保する方法でのその実施。 (d) 適用されるバイオセーフティ、バイオセキュリティ、およびデータ保護 基準 に従ってその実装を行う。 (e) 堅牢で包括的、透明性のある、加盟国主導の科学に基づいた ガバナンス、レビューおよび説明責任メカニズム の開発。 (f) PABS の資料および情報に関する知的財産権の取得を求めていないこと。および A/INB/9/3 Rev.1

13 (g) 生物多様性条約および 遺伝資源へのアクセスおよびその利用から生じる利益の公正かつ公平な分配に関する名古屋議定書の
目的と一致し、かつそれに反しない方法でのその実施。 PABS システムのプロバイダーとユーザーに法的確実性を提供することを目的として、また、名古屋議定書第 4 条第 4 項の意味の範囲内で 、特殊な国際アクセスおよび利益共有 手段として PABS システムを認識することを目的としています。 3. PABS システムは、少なくとも次の構成要素と要素を備えなければなりません。 (a) 様式、決定される契約条件に従って、 PABS の資料と情報、およびすべての関連情報を迅速、体系的かつタイムリーに共有すること。同意した。 (b) PABS の資料および情報へのアクセスから生じる金銭的および非金銭的利益の、公正、公平かつタイムリーな分配。これは 、決定および合意される 方式、条件に従って行わ れます。 (i) パンデミックが発生した場合、 安全で有効かつ有効な パンデミック生産物 の 20% (10% は WHO への寄付として、10% は手頃な価格で) への WHO によるリアルタイムのアクセス-関連する健康製品。 (ii) PABS システム利用者からの年間拠出金は、 本条第 6 項に従い、定義される様式、契約条件に基づいて、WHO によって管理されるものとする 。 (c ) 本条第 3 項 (b) に規定されているパンデミック関連の健康製品 の公平かつ公平な配分と流通を確保するためのメカニズムは、第 3 項のとおり、公衆衛生上のリスク、ニーズ、需要を考慮して開発されるものとする。この記事の6。 4. PABS システムには追加の利益共有オプションもあり、これには以下が含まれる場合があります。 (a) 能力開発活動、科学および 研究協力、非独占的ライセンス契約、譲渡の取り決めなどの 自発的な非金銭的貢献 公衆衛生期間におけるパンデミック関連の健康製品の購入に関する 第 11 条、段階的価格設定またはその他の費用関連の取り決め（無損失/無利益損失取り決めなど） に基づく、関連する診断、治療薬、またはワクチンの技術とノウハウ

国際的に懸念される緊急事態またはパンデミック。
(b) WHO が調整する研究室ネットワーク内の研究室に対し、PABS の材料と情報の研究に関連する科学プロジェクトへの発展途上国の科学者の参加を積極的に求めるよう奨励 する
。 5. 管轄区域内にパンデミック関連の健康製品を製造する製造施設を有する各締約国 は、WHO と関連製造業者との間で合意されるスケジュールに従って、当該製品の輸出を促進するために必要なあらゆる措置を講じるものとする 。 6. PABS システムの方式、契約条件、および運用上の寸法は、 2026 年 5 月 31 日までに運用開始される法的拘束力のある文書でさらに定義されるものとします 。 A/INB/9/3 Rev.1

14
第 13 条 サプライチェーンおよび物流1. パンデミック関連の健康製品への公平、タイムリーかつ手頃な価格のアクセス
を強化するために、グローバル サプライ チェーンおよび物流ネットワーク (ネットワーク) がここに設立されます。このネットワークは、WHOが締約国およびその他の関連する 国際的および地域的利害関係者 と協力して開発、調整、招集する
ものとする。締約国は、二国間 寄付協定 よりも、公衆衛生上のリスクとニーズに基づいた公平な配分のため、グローバルサプライチェーンおよび物流ネットワークを通じた共有を優先するものとする。 2. 締約国会議は、最初の会議で、ネットワークの構造と様式を定義するものとする 。 これは、以下を確保することを目的とするものとする 。 (b) ネットワークの機能は、 その機能を実行するのに最適な組織によって遂行されます。 (c) 発展途上国のニーズと、 脆弱な環境や人道的環境にある人々を含む 弱い立場にある人々のニーズを考慮する。 (d) パンデミック関連の健康製品の公平な割り当て。 (e ) ネットワークの機能とガバナンスにおける説明責任と透明性。 3. 締約国は 、パンデミック中およびパンデミックの合間に締約国およびその他の利害関係者によって提供される サポートを含む、ネットワークの運営を定期的にレビューするものとします。 4. パンデミック中、緊急貿易措置は的を絞った、比例的、透明性のある 一時的なものとし、貿易に対する不必要な障壁やパンデミック関連の健康製品のサプライチェーンの混乱を生じさせてはならない 。 5. パンデミックの間、人道援助要員、その 輸送手段、物資および装備、パンデミック関連の健康製品への迅速かつ妨げのないアクセスは、国際 人道法 を含む国際法の関連規定と一致する方法で促進されるものとする。法律を遵守し 、人道支援の提供における人道、中立、公平、独立の原則を尊重します。 6. パンデミック時のワクチンおよび治療関連の補償および責任を管理するための多国間システム を検討するものとします。

7. WHOは、ネットワークの招集者として、本条の実施に関連するすべての事項について 締約国会議に定期的に報告するものとする。
第13条の2国内調達および流通
1. 各締約国は、パンデミック関連の健康製品の製造業者との購入契約の関連条件を
合理的なできるだけ早い機会に公表し、
適用される法律に従って、かかる開示を制限する機密保持条項を除外するものとします。適切な。
地域的および世界的な購買メカニズムも同様のことを奨励されるものとします。
A/INB/9/3 Rev.1

15
2. パンデミック中、そうする立場にある各締約国は、利用可能な資源の範囲内で、
適用される法律に従い、関連する診断薬、治療薬、またはワクチンの調達総額の一部を
適時に各国で使用するために確保しなければならない。公衆
衛生のニーズと需要を満たすという課題に直面しています。 3. 各締約国は 、パンデミック関連の健康製品
の合理的な使用を促進し、無駄を削減するために適切な措置を講じるものとする。 4. 各締約国は、国内のパンデミックへの備え と対応 に必要と予想される量を不必要に超える パンデミック関連の健康製品の国家備蓄を避けることを約束する。 5. パンデミック関連の健康製品を国、組織、または ネットワークによって促進されるメカニズムと共有する場合、そのような製品は指定されておらず、 必要なすべての適切 かつ関連する条件、要件、特性、および補助製品を伴うものとします。配布、管理、調剤のため。 6. 各当事者は、新型パンデミックワクチンの供給または購入に関する契約において 、購入者/受領者補償条項（存在する場合）が例外的に規定され、 期限付きであることを確保するよう努めるものとする。 第 14 条 規制の強化1. 各締約国は、WHO、他の締約国および関連組織との技術支援および協力 を通じたものを含め、パンデミック関連の健康製品の認可および承認に責任を負う 国内および必要に応じて地域の規制当局 を強化するものとする。また、 要求があった場合には、そのような製品の品質、安全性、有効性を確保することを目的としています。 2. 各締約国は 、パンデミック中のパンデミック関連の健康製品の効果的かつタイムリー な承認、有害事象の監視、および共有のための緊急規制認可を支援するための法的、行政的および財政的枠組みを 確実に整備するための措置を講じるものとする。 必要に応じて、WHO を通じて規制関係書類を提出する。 3. 各締約国は、関連法に従い、以下を行うものとする。 (a) パンデミック関連の健康製品の製造業者に対し、 関連する規制データを適時に作成および提出し、共通の技術データの開発に貢献することを奨励する。

文書を確認し、国の規制当局の認可と承認を熱心に追求し、
必要に応じて WHO および WHO にリストされている当局による事前資格審査を取得します。 (b) パンデミック関連の健康製品の使用を認可または承認する国および該当する場合は地域のプロセスに関する情報を公的に公開し、必要に応じて、そのようなパンデミック関連の健康製品に対して規制依存
プロセス または その他の関連する規制経路を採用する。これはパンデミック中に効率を高めるためにアクティブ化される可能性があり、 そのような情報をタイムリーに更新するものとします。 4. 締約国は、必要に応じて、 規格外および偽造されたパンデミック関連の健康製品に対する迅速な警報システムを監視、規制し、強化するものとします。 5. 両当事者は、 A/INB/9/3 Rev.1 を含む適用される国際規格、ガイダンス、プロトコルに従って、技術的および規制上の要件と手順を調整し、可能な場合には調和させるものとします。

規制への依存と相互承認を対象とし、他の締約国とのパンデミック関連の健康製品の品質、安全性、有効性に関する関連情報、データ、評価を公開するものと
する
。
第 15 条 補償および責任の管理 ?この条項の規定は、
第 13 条および第 13 条の 2 に統合されました（番号付けの目的のみに保持されています）
。この条の規定は
第 19 条と統合された（番号付けの目的のみに保持）
第 17 条 政府全体および社会全体のアプローチ
1. 締約国は、政府全体および社会全体のアプローチを採用することが奨励される。 パンデミックの予防、備え、対応に対するコミュニティ
の準備と回復力をコミュニティが所有し、それに貢献できるようにすることを含む、国家レベルでの社会アプローチ。 2. 各締約国は、パンデミックの予防、準備、対応のための国家多部門の調整メカニズムを確立または強化し、維持することが求められる 。 3. 各締約国は、自国の状況を考慮して、以下の事項を行うものとする。 (a) 計画、意思決定、 実施、監視および評価 における社会全体のアプローチの一環として、地域 社会およびその他の関連する利害関係者の効果的かつ有意義な関与を促進する。、また効果的なフィードバックの 機会も提供するものとします。 ( b ) パンデミックの社会経済的影響を緩和し、パンデミック に対する迅速かつ回復力のある対応を促進するために 、特に弱い立場にある人々に対して、相互支援のために地域社会のソーシャル・キャピタルを動員するなど、 国の公衆衛生および社会政策を強化するための適切な措置を講じること。 4. 各締約国は、各国の状況に応じて、民間部門 や民間 部門を含む関連する利害関係者との協力を促進する透明性のある方法で、パンデミック前、パンデミック後、およびパンデミック間期に対処する包括的な国家パンデミック予防、 準備および対応計画を策定するものとする。社会に貢献し、あらゆる形態の利益相反を回避します。 5. 締約国は、必要に応じて国内法および/または国内法および政策に従って 、教育および地域社会への関与の開発および実施を促進および促進するものとする。

パンデミックと公衆衛生上の緊急事態に関するプログラムを、関係するすべての利害関係者の参加を得て
、脆弱な状況にある人々を含むアクセス可能な方法で実施する。
第 18 条 コミュニケーションと国民の意識
1. 締約国は、国民の科学、公衆衛生、パンデミックに関するリテラシーを強化するとともに、
パンデミックとその原因、影響、推進要因に関する透明で正確な、科学と証拠に基づいた情報へのアクセスを強化するものとする
。特にリスクコミュニケーションと効果的な
コミュニティレベルの関与を通じて。
2. 締約国は、必要に応じて、
パンデミックにおける公衆衛生および社会的措置の順守、および科学および公衆衛生
機関、当局および機関への信頼を妨げるまたは強化する要因に関する政策を知らせるための研究を実施するものとする。
A/INB/9/3 Rev.1

17
第 19 条 実施のための国際協力と支援
1. 締約国は、 すべての締約国のパンデミックの予防、準備および対応能力、特に発展途上の能力を
持続的に強化するために、直接または関連国際機関を通じて、自由に使える手段および資源の範囲内で協力するものとする。
国の政党。このような協力は、
相互に合意した条件での技術移転、技術的、科学的、
法律的専門知識の共有を促進するとともに、
本協定の規定を実施するための手段と資源が不足している締約国に対する財政援助と能力強化への支援を促進するものとする。 、そして 、本協定から生じる義務を履行するために、締約国
の要請に応じて、必要に応じて関連組織と協力して、WHOによって促進され、提供されるものとする。 2. 開発途上締約国がこの協定の規定を履行できるようにするために、開発途上締約国 の特有のニーズ及び特殊な状況に特別の配慮が払われるものとする。 3. 両当事者は 、本協定の目的を達成するために 、関連する法的文書および枠組み、 関連する世界的、地域的、小地域的および部門別の組織および利害関係者間の協力を強化および強化することを通じて、パンデミックの予防、準備および対応のために協力し協力するものとする。 国際保健規則 (2005 年)に基づいて提供される支援と緊密に調整します。 第 20 条 持続可能な資金調達 1. 締約国は、 本協定および国際保健規則（2005 年）の実施のために、包括的かつ透明性のある方法で、持続可能かつ予測可能な資金調達を強化するものとする。 2. この点に関して、各締約国は、自由に使える手段と資源の範囲内で、次のことを行うものとする。 (a) パンデミックの予防、準備、対応のための国内資金を必要に応じて維持または増加する 。 (b) WHOパンデミック協定の実施において締約国、特に発展途上国の締約国を支援するために、補助金や 譲許的融資を含む 追加の財源を動員する。 (c) 関連する二国間、地域および/または多国間 資金調達メカニズムの中で、透明性のある財政を含む革新的な資金調達措置を 検討し、必要に応じて推進する。

特に財政的制約に直面している発展途上国 向けに、パンデミックの予防、準備、対応のための計画を再プログラムする。 (d) 各国の負担を
最小限に抑え、効率性と一貫性を大規模に向上させ、透明性を高め、開発途上国のニーズと国家的優先事項に対応するために、既存の金融機関のガバナンスと運営 モデルを奨励する。 3. 持続可能な資金支援を提供し、パンデミックの予防、準備および対応能力を強化および拡大し 、特に開発途上締約国においてゼロデイに必要なサージ対応を提供するため、 調整金融メカニズム（メカニズム）がここに確立 される。このメカニズムは、特に： （a）戦略的意思決定を支援するために関連するニーズとギャップの分析を実施し、 パンデミック協定の財務および実施戦略を5年ごとに策定し、 検討のために締約国会議に提出する。 A/INB/9/3 Rev.1

18
(b) パンデミックの予防、
準備、対応、および国際保健規則（2005 年）関連能力への資金提供のための調和、一貫性、調整を促進する。
(c) 本協定の実施を支援する目的を果たすために利用可能なすべての資金源を特定し
、そのような手段と関連情報、およびそのような手段から各国に割り当てられた資金のダッシュボードを維持する
。
(d) 必要に応じて、締約国会議からの命令に従って、 財務戦略および実施戦略の
支援を促進するために、関連する特定された資金調達手段および事業体との作業協定を確立する。 (e) パンデミックの予防、備え、対応を強化するための財源を 特定し、申請する際に、要請に応じて締約国に助言と支援を提供する。 (f) パンデミックの予防、備え、対応を強化するための国際的な取り組みから恩恵を受ける分野で活動する 関連利害関係者など、利益相反のない、 パンデミックの予防、備え、対応を 支援する組織やその他の 団体への自発的な金銭拠出を活用する。。 4. メカニズムは締約国会議の権限と指導の下で機能し 、締約国会議に対して責任を負うものとする。締約国会議は、 WHO パンデミック協定 の発効後 12 か月以内に、メカニズムとその運用とガバナンスのための方式に関する付託条件を採択するものとする。 5. 締約国会議は、必要に応じて、 本条のパラグラフ 3(a) に記載されているパンデミック協定の財務および実施戦略を定期的に検討するものとします。締約国は 、パンデミックの予防、準備および対応の強化 のために外部の財政的支援を提供する場合、必要に応じてそれに合わせるよう努めるものとする。 第 3 章。制度上の取り決めと最終規定 第 21 条 締約国会議 1. ここに締約国会議が設置される。 2. 締約国会議は、WHO パンデミック協定の実施状況を定期的に評価し、その機能を 5 年ごとにレビューし、必要な決定を下すものとする。

その効果的な実施を促進します。この目的のために、WHO は
、WHO パンデミック協定の目的を達成するために、必要に応じて措置を講じるものとする。
3. 締約国会議の最初の会合は、
WHO パンデミック協定発効後 1 年以内に世界保健機関によって招集されるものとする。
締約国会議は、最初の会合でその後の定例会合の開催地と時期を決定する
。
4. 締約国会議の臨時会合は、
締約国会議により必要とみなされる他の時期に、または締約国の書面による要請に応じて開催されるものとする。ただし
、要請が書面で伝達されてから 6 か月以内に限ります。事務局が締約国に提出した場合、
締約国の少なくとも 3 分の 1 が支持する。このような臨時会期は
、国家元首または政府首脳レベルで招集される場合がある。
A/INB/9/3 Rev.1

19
5. 締約国会議は、最初の会合において、その手続き規則
および議事へのオブザーバーの参加基準を合意により採択するものとする。
6. 締約国会議は、合意により、それ自体の財務規則を採択するとともに、
設立される補助機関の資金調達および事務局の機能を管理するものとする。
各定例会においては、次の定例会までの会計期間の予算を採択するものとする。
7. 締約国会議は、必要に応じて補助機関を設立し、
そのような機関の条件と方式を決定することができる。
第 22 条 投票権1. 本条第 2 項
に規定する場合を除き、WHO パンデミック協定の各締約国は 1 票を有するものとする。 2. WHO パンデミック協定の締約国である地域経済統合機関は、 その権限の範囲内の問題について、WHO パンデミック協定の締約国である加盟国の数に等しい投票数で投票する権利を行使するものとする 。かかる組織は、 加盟国のいずれかが投票権を行使した場合には投票権を行使してはならないし、その逆も同様である。 第 23 条 締約国会議への報告1. 各締約国は、 WHO パンデミック協定の履行 について、事務局を通じて締約国会議に定期的に報告するものとする。 2. すべての締約国が提出する報告書の頻度と形式は、 締約国会議によって決定されるものとする。 3. 締約国会議は、要請に応じて、 開発途上締約国のニーズに特に配慮しつつ、本条に基づく義務を果たす締約国を支援するための適切な措置を講じるものとする 。 4. WHO パンデミック協定に基づく報告および情報交換は 、機密保持およびプライバシーに関して、必要に応じて国内法および/または国内法に 従うものとします。両当事者は 、相互に合意したとおり、交換される機密情報を保護するものとします。締約国によって提出された定期報告書は、 事務局によってオンラインで公開されるものとする。 第 24 条 事務局 1. WHO パンデミック協定の事務局機能は、 WHO 事務局によって提供されるものとする。

2. 事務局は、必要に応じて、WHO パンデミック協定によって指定された機能、
および締約国会議によって決定されるか、または
WHO パンデミック協定に基づいて割り当てられるその他の機能を実行するものとします。
3. WHO パンデミック協定のいかなる規定も、WHO 事務局長を含む WHO 事務局に、 必要に応じて国内法および/または国内法、あるいは国家の政策
を指示、命令、変更、またはその他の方法で規定する権限を与えるものとして解釈されないものとします。締約国は 、旅行者の入国禁止や受け入れ、ワクチン接種の義務付けや治療法や診断上の措置を課す、あるいはロックダウンを実施するなど、特定の行動を取ることを
義務付けるか、その他の要件を課すことを目的としています 。 A/INB/9/3 Rev.1

20
第 25 条 紛争の解決
1. WHO パンデミック協定の解釈または適用に関して 2 つ以上の締約国間で紛争が生じた場合、関係締約国は、外交ルートを通じて 、交渉またはその他の平和的方法による紛争の解決を
模索するものとする。 善処、調停、調停
など、自らが選択した手段。上記の
方法で解決に至らなかった場合、両当事者は、常設仲裁裁判所の 規則 に従って、当事者が合意した場合には臨時仲裁に頼ることも
含め、共同協議を通じて紛争の解決を模索し続けることができます。2012 年以降のルール。仲裁に同意した当事者は、仲裁 判断を拘束力のある最終的なものとして受け入れるものとします。 2. 本条の規定は、 議定書に別段の定めがない限り、議定書締約国間のあらゆる議定書に適用されるものとする。 第 26 条 他の国際協定および国際文書との関係1. WHO パンデミック協定の解釈および適用は 、国連憲章および世界保健機関憲章 に従うものとする。 2. 締約国は、WHO パンデミック協定と国際保健 規則 (2005 年) が互換性があり、相互に補強するように解釈されるべきであることを認識する。 第 27 条 留保 WHO パンデミック 協定の目的および目的と矛盾しない限り、WHO パンデミック協定に対して留保を行うことができます。 第 28 条 宣言および声明 1. 第 27 条は、国家または地域の経済統合組織が WHO パンデミック協定に署名、批准、承認、受諾または加入する際、その 表現や名称にかかわらず、宣言または声明を行うことを妨げるものではない。とりわけ、 その法律および規制とWHOパンデミック協定の規定との調和を考慮すること。 ただし、そのような宣言または声明が 、その適用におけるWHOパンデミック協定 の規定の法的効果を除外または変更することを意図していないことを条件とする。その州または地域の経済統合 組織に。 2. 本条に従って行われた宣言または声明は、寄託者によって WHO パンデミック協定のすべての締約国に回覧されるものとする。

第 29 条 修正
1. いずれの締約国も、附属書を含む WHO パンデミック協定の修正を提案することができ
、かかる修正は締約国会議で検討されるものとする。
2. 締約国会議は、WHO パンデミック協定の修正を採択することができる。 WHO パンデミック協定の修正案の文言は 、採択が提案される会期の少なくとも 6 か月前までに事務局から締約国
に通知されるものとする。
事務
局はまた、修正案をWHOパンデミック
協定の署名者、および情報として寄託者に通知するものとする。
A/INB/9/3 Rev.1

21
3. 締約国は、WHO パンデミック協定の修正案を
全会一致で採択するためにあらゆる努力を払うものとする。合意に向けたあらゆる努力が尽くされ、合意に達しなかった場合、最後の手段として 、会議に出席し投票する
締約国の4分の3の多数決によって修正案が採択される可能性がある。
この条項の目的上、出席し投票する当事者とは、
出席し、賛成票または反対票を投じる当事者を意味します。採択された修正は
事務局から寄託者に通知され、寄託者は受諾のためにすべての締約国に回覧するものとする。
4. 補正に関する受諾書は寄託者に寄託されるものとする。
本条の第 3 項に従って採択された修正は、それを受諾した締約国に対して、締約国の少なくとも 3 分の 2 が寄託者により受領文書を受領した日から 90 日目に発効するものと する
。
WHOのパンデミック協定。 5. 修正案は、他の締約国に対して 、当該締約国が当該修正案の受諾文書を寄託者に寄託した
日から 90 日目に発効するものとする。 第 30 条 附属書1. WHO パンデミック協定の附属書は 、第 29 条に定める手順に従って 提案、採択され、発効するものとする。 2. WHO パンデミック協定の附属書は、その不可欠の部分を形成するものとする。 別途明示的に規定されている場合を除き、WHO パンデミック協定への言及は、同時に その付属文書への言及を構成します。 第 31 条 議定書 1. いずれの締約国も、WHO パンデミック協定に議定書を提案することができる。かかる提案は 締約国会議によって検討されるものとする。 2. 締約国会議は、WHO パンデミック協定の議定書を採択することができる。これらの議定書を採用する際には 、第 29 条第 3 項の意思決定条件が準用されるものとします。 世界保健機関憲法第 21 条に基づいて議定書が採択されるよう提案された場合には 、採択の検討のためにさらに世界保健総会に提出されるものとする。 3. 提案された議定書の本文は、 採択が提案される締約国会議の会期の少なくとも 6 か月前に事務局によって締約国に通知されるものとする。

4. WHO パンデミック協定の締約国ではない国でも、議定書にその旨が定められて
いる限り、議定書の締約国となることができます。
5. WHO パンデミック協定の議定書は、当該議定書の締約国のみを拘束するものとする
。議定書の締約国のみが、
問題の議定書にのみ関係する事項について決定を下すことができます。
6. 議定書発効の要件および
議定書の修正手順は、その文書によって確立されるものとする。
第 32 条 脱退
1. WHO パンデミック協定が締約国に対して発効した日から 2 年を経過した後はいつでも
、締約国は寄託者に書面で通知することにより協定から脱退することができる
。
A/INB/9/3 Rev.1

22
2. かかる引き出しは、寄託者による引き出し通知の受領日から 1 年が経過した時点、または 引き出し
通知に指定されているそれ以降の日付に発効するものとします。 3. 国家は、WHO パンデミック協定の締約国であった間に発生した義務の離脱を理由に解任されず、また離脱は 、この協定の履行によって生じた当該国の 権利、義務、または法的状況に影響を与えないものとする。 その州における終了前の合意。 4. WHO パンデミック協定から離脱した締約国は、 当該締約国が他の協定から正式に離脱し、以下の規則に従って離脱しない限り、自らが締約国となっている議定書や関連文書からも離脱 したとはみなされないものとする。関連する条件 がある場合は、それも含めて。 第 33 条 署名1. 本協定は、世界保健機関のすべての加盟国、および世界保健機関には加盟していないが 国連の加盟国 または非加盟オブザーバー国である国、および地域ごとに 署名を受け付けるものとする。経済統合組織。 2. 本協定は 、第 77 回 世界保健総会での採択後、2024 年 5 月 XX 日から 2024 年 6 月 XX 日まで、ジュネーブの世界保健機関本部で署名を受け付け 、その後はニューデリーの国連本部で署名を受け付けるものとする。ヨーク、 2024 年 6 月 XX 日から 2025 年 6 月 XX 日まで。 第 34 条 批准、受諾、承認、正式な確認または加入1. WHO パンデミック協定は 、すべての国による批准、受諾、承認または加入、および正式な確認または加入の 対象となるものとする。地域経済統合組織による。本契約およびその議定書は 、本契約の署名が終了した 日の翌日から加入できるものとします。批准、受諾、承認、正式な 確認または加入の文書は寄託者に寄託されるものとする。 2. 加盟国のいずれも締約国ではないにもかかわらず、WHO パンデミック協定の締約国となった地域経済統合組織は、 WHO パンデミック協定またはその議定書 に基づくすべての義務に拘束されるものとする。そういった地域経済の場合には、

1 つ以上の加盟国が WHO パンデミック協定の締約国である統合機関、地域経済統合機関およびその加盟国は 、協定に基づく義務の履行についてそれぞれの責任
を決定するものとする。
このような場合、地域経済統合機関とその加盟国は 、WHO パンデミック協定に基づく権利を同時に
行使する権利を有しないものとする。 3. 地域経済統合機関は、正式な確認に関連する文書または加入文書において、 WHO パンデミック協定およびその議定書によって規定される事項 に関する自らの権限の範囲を宣言するものとする。これらの組織は また、寄託者に通知し、寄託者は その権限の範囲の大幅な変更を締約国に通知するものとします。 A/INB/9/3 Rev.1

23
第 35 条 発効1. 本協定は 、60 番目の批准書、受諾書、承認書、正式な確認書、または寄託者への加入書を
寄託した日から 30 日目に発効するものとする 。 2. WHO パンデミック協定を批准、受諾もしくは承認するか、 本条第 1 項に定める発効条件が満たされた後に それに加入する各国について、 WHO パンデミック協定は 30 日目に発効するものとする。 批准、受諾、承認、加入の文書の寄託日。 3. 本条第 1 項に規定 された発効条件が満たされた後に 正式確認書または加入書を寄託した各地域経済統合組織について、WHO パンデミック協定は 30 日目に発効するものとする。正式な確認書または加入書の寄託日以降。 4. 本条の目的上、地域経済統合機関により寄託された文書は、その地域 経済統合機関 の加盟国により寄託された文書に追加として数えられないものとする。 第 36 条 寄託者 国連事務総長は、WHO パンデミック 協定およびその修正、ならびに WHO パンデミック協定の条項に従って採択された議定書および附属書の寄託者となるものとする。 第 37 条 本物の文書 WHO パンデミック協定の原本は、アラビア語、中国語、英語、フランス語、ロシア語、スペイン語の文書も同様に本物であるものとし、 国連事務 総長に寄託するものとする。 = = =

https://apps.who.int/gb/inb/e/e_inb-9-resumed-session.html

https://apps.who.int/gb/inb/pdf_files/inb9/A_inb9_3Rev1-en.pdf

RESUMED NINTH MEETING OF THE
INTERGOVERNMENTAL NEGOTIATING BODY TO
DRAFT AND NEGOTIATE A WHO CONVENTION,
AGREEMENT OR OTHER INTERNATIONAL
INSTRUMENT ON PANDEMIC PREVENTION,
PREPAREDNESS AND RESPONSE A/INB/9/3 Rev.1
Provisional agenda item 2 22 April 2024
Proposal for the WHO Pandemic Agreement
A/INB/9/3 Rev.1

2
Contents
Chapter I. Introduction ………………………………………………………………………………………………….. 5
Article 1. Use of terms …………………………………………………………………………………………………. 5
Article 2. Objective ……………………………………………………………………………………………………… 6
Article 3. Principles ……………………………………………………………………………………………………… 6
Chapter II. The world together equitably: Achieving equity in, for and through pandemic
prevention, preparedness and response …………………………………………………………….. 7
Article 4. Pandemic prevention and public health surveillance ………………………………………….. 7
Article 5. One Health …………………………………………………………………………………………………… 8
Article 6. Preparedness, readiness and health system resilience …………………………………………. 8
Article 7. Health and care workforce ……………………………………………………………………………… 9
Article 8. Preparedness monitoring and functional reviews ……………………………………………… 10
Article 9. Research and development ……………………………………………………………………………. 10
Article 10. Sustainable and geographically diversified production, and technology
transfer and know-how …………………………………………………………………………………. 10
Article 11. Transfer of technology and know-how for the production of pandemic-related
health products ……………………………………………………………………………………………. 11
Article 12. Access and benefit sharing ……………………………………………………………………………. 12
Article 13. Supply chain and logistics …………………………………………………………………………….. 14
Article 13bis. National procurement and distribution ……………………………………………………………. 14
Article 14. Regulatory strengthening ……………………………………………………………………………… 15
Article 15. Compensation and liability management ………………………………………………………… 16
Article 16. International collaboration and cooperation …………………………………………………….. 16
Article 17. Whole-of-government and whole-of-society approaches ………………………………….. 16
Article 18. Communication and public awareness ……………………………………………………………. 16
Article 19. International cooperation and support for implementation ………………………………… 17
Article 20. Sustainable financing …………………………………………………………………………………… 17
Chapter III. Institutional arrangements and final provisions ……………………………………………….. 18
Article 21. Conference of the Parties ……………………………………………………………………………… 18
Article 22. Right to vote ……………………………………………………………………………………………….. 19
Article 23. Reports to the Conference of the Parties …………………………………………………………. 19
Article 24. Secretariat …………………………………………………………………………………………………… 19
Article 25. Settlement of disputes ………………………………………………………………………………….. 20
Article 26. Relationship with other international agreements and instruments ……………………… 20
Article 27. Reservations ……………………………………………………………………………………………….. 20
A/INB/9/3 Rev.1

3
Article 28. Declarations and statements ……………………………………………………………………………20
Article 29. Amendments ………………………………………………………………………………………………..20
Article 30. Annexes ………………………………………………………………………………………………………21
Article 31. Protocols ……………………………………………………………………………………………………..21
Article 32. Withdrawal…………………………………………………………………………………………………..21
Article 33. Signature ……………………………………………………………………………………………………..22
Article 34. Ratification, acceptance, approval, formal confirmation or accession ………………….22
Article 35. Entry into force …………………………………………………………………………………………….23
Article 36. Depositary ……………………………………………………………………………………………………23
Article 37. Authentic texts ……………………………………………………………………………………………..23
A/INB/9/3 Rev.1

4
The Parties to the WHO Pandemic Agreement,
1. Recognizing that States bear the primary responsibility for supporting the health and well-being
of their peoples, and that States are fundamental to strengthening pandemic prevention, preparedness
and response,
2. Recognizing that differences in the levels of development of Parties engender different capacities
and capabilities in pandemic prevention, preparedness and response and acknowledging that unequal
development in different countries in the promotion of health and control of disease, especially
communicable disease, is a common danger that requires support through international cooperation,
including the support of countries with greater capacities and resources, as well as predictable,
sustainable and sufficient financial, human, logistical, technological and technical resources,
3. Recognizing that the World Health Organization is the directing and coordinating authority on
international health work, including on pandemic prevention, preparedness and response,
4. Recalling the Constitution of the World Health Organization, which states that the enjoyment of
the highest attainable standard of health is one of the fundamental rights of every human being without
distinction of race, religion, political belief, economic or social condition,
5. Recalling that the Convention on the Elimination of All Forms of Discrimination against Women,
adopted by the United Nations General Assembly on 18 December 1979, provides that States Parties to
that Convention shall take appropriate measures to eliminate discrimination against women in the field
of health care, and that Sustainable Development Goal 5 aims “to achieve gender equality and empower
all women and girls”,
6. Recognizing that the international spread of disease is a global threat with serious consequences
for lives, livelihoods, societies and economies that calls for the widest possible international and regional
collaboration, cooperation and solidarity with all people and countries, especially developing countries,
and notably least developed countries and small island developing States, in order to ensure an effective,
coordinated, appropriate, comprehensive and equitable international response, while reaffirming the
principle of the sovereignty of States in addressing public health matters,
7. Deeply concerned by the inequities at national and international levels that hindered timely and
equitable access to coronavirus disease (COVID-19) pandemic-related health products, and the serious
shortcomings in pandemic prevention, preparedness and response,
8. Recognizing the critical role of whole-of-government and whole-of-society approaches at national
and community levels, through broad social participation, and further recognizing the value and
diversity of the culture and knowledge of indigenous peoples in strengthening pandemic prevention,
preparedness, response and health systems recovery,
9. Recognizing the importance of ensuring political commitment, resourcing and action through
cross-sector collaborations for pandemic prevention, preparedness, response and health systems
recovery,
10. Reaffirming the importance of multisectoral collaboration at national, regional and international
levels to safeguard human health, including through a One Health approach,
A/INB/9/3 Rev.1

5
11. Recognizing the importance of rapid and unimpeded access of humanitarian relief in accordance
with international law, including international human rights law and international humanitarian law, and
the respect of the principles of humanity, neutrality, impartiality and independence for the provision of
humanitarian assistance,
12. Reiterating the need to work towards building and strengthening resilient health systems, with
adequate numbers of skilled, trained and protected health and care workers to respond to pandemics, to
advance the achievement of universal health coverage, particularly through a primary health care
approach; and to adopt an equitable approach to mitigate the risk that pandemics exacerbate existing
inequities in access to health care services,
13. Recognizing the importance of building trust and ensuring the timely sharing of information to
prevent misinformation, disinformation and stigmatization,
14. Recognizing that intellectual property protection is important for the development of new
medicines, recognizing the concerns about its effects on prices and recalling that the Agreement on
Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) does not, and should not,
prevent Member States from taking measures to protect public health,
15. Recalling the sovereign right of States over their biological resources and the importance of
collective action to mitigate public health risks, and underscoring the importance of promoting the
timely, safe, transparent, accountable and rapid sharing of materials and information on pathogens with
pandemic potential for public health purposes, and, on an equal footing, the timely, fair and equitable
sharing of benefits arising therefrom, taking into account relevant national, domestic, and international
laws,
16. Stressing that adequate pandemic prevention, preparedness, response and health systems recovery
is part of a continuum to combat other health emergencies and achieve greater health equity through
resolute action on the social, environmental, cultural, political and economic determinants of health, and
17. Recognizing the importance and public health impact of growing threats such as climate change,
poverty and hunger, fragile and vulnerable settings, weak primary health care and the spread of
antimicrobial resistance,
Have agreed as follows:
Chapter I. Introduction
Article 1. Use of terms
For the purposes of the WHO Pandemic Agreement:
(a) “manufacturer” means public or private entities that develop and/or produce
pandemic-related health products;
(b) “One Health approach” means an integrated, unifying approach that aims to sustainably
balance and optimize the health of people, animals and ecosystems. It recognizes that the health
of humans, domestic and wild animals, plants and the wider environment (including ecosystems)
is closely linked and interdependent;
A/INB/9/3 Rev.1

6
(c) “PABS material and information” means the biological material from a pathogen with
pandemic potential, as well as sequencing information relevant to the development of
pandemic-related health products;
(d) “pandemic-related health products” means the safe, effective, quality and affordable
products that are needed for pandemic prevention, preparedness and response, which may include,
without limitation, diagnostics, therapeutics, vaccines and personal protective equipment;
(e) “Party” means a State or regional economic integration organization that has consented to
be bound by this Agreement, in accordance with its terms, and for which this Agreement is in
force;
(f) “pathogen with pandemic potential” means any pathogen that has been identified to infect
a human and that is novel (not yet characterized) or known (including a variant of a known
pathogen), potentially highly transmissible and/or highly virulent, with the potential to cause a
public health emergency of international concern;
(g) “persons in vulnerable situations” means individuals, groups or communities with a
disproportionate increased risk of infection, severity, disease or mortality in the context of a
pandemic. This is understood to include persons in fragile and humanitarian settings;
(h) “regional economic integration organization” means an organization that is composed of
several sovereign States and to which its Member States have transferred competence over a range
of matters, including the authority to make decisions binding on its Member States in respect of
those matters;1 and
(i) “universal health coverage” means that all people have access to the full range of quality
health services they need, when and where they need them, without financial hardship. It covers
the full continuum of essential health services, from health promotion to prevention, treatment,
rehabilitation and palliative care.
Article 2. Objective
1. The objective of the WHO Pandemic Agreement, guided by equity and the principles further set
forth herein, is to prevent, prepare for and respond to pandemics.
2. In furtherance of this objective, the provisions of the WHO Pandemic Agreement apply both
during and between pandemics, unless otherwise specified.
Article 3. Principles
To achieve the objective of the WHO Pandemic Agreement and to implement its provisions, the
Parties shall be guided, inter alia, by the following:
1. the sovereign right of States to adopt, legislate and implement legislation, within their jurisdiction,
in accordance with the Charter of the United Nations, the WHO Constitution and the principles of
international law, and their sovereign rights over their biological resources;
1 Where appropriate, “national” will refer equally to regional economic integration organizations.
A/INB/9/3 Rev.1

7
2. full respect for the dignity, human rights and fundamental freedoms of all persons, and the
enjoyment of the highest attainable standard of health of every human being;
3. full respect of international humanitarian law for effective pandemic prevention, preparedness
and response;
4. equity as a goal and outcome of pandemic prevention, preparedness and response, striving for the
absence of unfair, avoidable or remediable differences among and between individuals, communities
and countries;
5. solidarity with all people and countries in the context of health emergencies, inclusivity,
transparency and accountability to achieve the common interest of a more equitable and better prepared
world to prevent, respond to and recover from pandemics, recognizing different levels of capacities and
capabilities; and
6. the best available science and evidence as the basis for public health decisions for pandemic
prevention, preparedness and response.
Chapter II. The world together equitably: Achieving equity in, for and through
pandemic prevention, preparedness and response
Article 4. Pandemic prevention and public health surveillance
1. The Parties shall cooperate with one another, in bilateral, regional and multilateral settings, to
progressively strengthen pandemic prevention and public health surveillance capacities, consistent with
the International Health Regulations (2005), and taking into account national and regional
circumstances.
2. Each Party shall develop, strengthen, implement, periodically update and review comprehensive
multisectoral national pandemic prevention and public health surveillance plans that are consistent with
and supportive of the effective implementation of the International Health Regulations (2005) and in
accordance with its capacities, and that cover, inter alia:
(a) collaborative surveillance;
(b) community-based early detection and control measures;
(c) water, sanitation and hygiene;
(d) routine immunization;
(e) infection prevention and control;
(f) zoonotic spill over and spillback prevention;
(g) laboratory biological risk management in order to prevent the accidental exposure to, the
misuse of or the inadvertent release of pathogens;
(h) vector-borne disease surveillance and prevention; and
A/INB/9/3 Rev.1

8
(i) antimicrobial resistance to address the pandemic-related risks associated with the
emergence and spread of pathogens that are resistant to antimicrobial agents.
3. The Parties recognize that environmental, climatic, social, anthropogenic and economic factors
increase the risk of pandemics and endeavour to identify these factors and take them into consideration
in the development and implementation of relevant policies, strategies and measures at the international,
regional and national levels, as appropriate, including by strengthening synergies with other relevant
international instruments and their implementation.
4. The Conference of the Parties may adopt, as necessary, guidelines, recommendations and
standards, including in relation to pandemic prevention capacities, to support the implementation of this
Article.
Article 5. One Health
1. The Parties commit to promote a One Health approach for pandemic prevention, preparedness
and response, recognizing the interconnection between people, animals and the environment, that is
coherent, integrated, coordinated and collaborative among all relevant organizations, sectors and actors,
taking into account national circumstances.
2. The Parties commit to identify and address the drivers of pandemics and the emergence and re-
emergence of disease at the human-animal-environment interface through the introduction and
integration of interventions into relevant pandemic prevention, preparedness and response plans.
3. Each Party shall, in accordance with its national context, protect human, animal and plant health,
with support from WHO and other relevant international organizations, by:
(a) implementing and regularly reviewing relevant national policies and strategies that reflect
a One Health approach as it relates to pandemic prevention, preparedness and response;
(b) promoting the effective and meaningful engagement of communities in the development
and implementation of policies, strategies and measures to prevent, detect and respond to
outbreaks; and
(c) promoting or establishing One Health joint training and continuing education programmes
for human, animal and environmental health workforces to build relevant and complementary
skills, capacities and capabilities.
4. The modalities, terms and conditions and operational dimensions of a One Health approach shall
be further defined in an instrument that takes into consideration the provisions of the International Health
Regulations (2005) and will be operational by 31 May 2026.
Article 6. Preparedness, readiness and health system resilience
1. Each Party commits to develop, strengthen and maintain a resilient health system, particularly
primary health care, for pandemic prevention, preparedness and response, taking into account the need
for equity, with a view to achieving universal health coverage.
2. Each Party commits, in accordance with its national and/or domestic law, as appropriate, and its
capabilities, to develop or strengthen, sustain and monitor health system functions and infrastructure,
including by adopting and/or developing policies, plans, strategies and measures, as appropriate, for:
A/INB/9/3 Rev.1

9
(a) the timely provision of, and equitable access to, scalable clinical care, quality routine and
essential health care services during pandemics, with a focus on primary health care, mental health
and psychosocial support and with particular attention to persons in vulnerable situations;
(b) post-pandemic health system recovery;
(c) laboratory and diagnostic capacities and associated national, regional and global networks,
through the application of relevant standards and protocols for laboratory biosafety and
biosecurity; and
(d) promoting the use of social and behavioural sciences, risk communication and community
engagement for pandemic prevention, preparedness and response.
3. The Parties, collaborating with WHO and relevant international organizations, shall endeavour to
identify, promote and/or strengthen, as appropriate, in accordance with national and/or domestic law, as
appropriate, relevant international data standards and interoperability that enable timely sharing of
public health data for preventing, detecting and responding to public health events.
4. With the aim of promoting and supporting learning among Parties, best practices, and
accountability and coordination of resources, an inclusive, transparent, effective and efficient pandemic
prevention, preparedness and response monitoring and evaluation system shall be developed,
implemented and regularly assessed, by WHO in partnership with relevant organizations, building on
relevant tools, on a timeline to be agreed by the Conference of the Parties.
Article 7. Health and care workforce
1. Each Party, in line with its respective capacities and national circumstances, shall take the
necessary steps to establish, safeguard, protect, invest in and sustain a multidisciplinary, skilled, trained
and diverse workforce to prevent, prepare for and respond to health emergencies closest to where they
start, including in humanitarian settings, while maintaining quality essential health services and essential
public health functions during pandemics.
2. Each Party shall take appropriate measures to protect and ensure the continued safety, well-being
and capacity of its health and care workforce, including by ensuring priority access to pandemic-related
health products during pandemics, thereby minimizing disruptions to the delivery of good quality
essential health services.
3. The Parties shall invest in establishing and sustaining a skilled, trained and coordinated
multidisciplinary global health emergency workforce deployable to support Parties upon request, based
on public health needs, to contain outbreaks and prevent the escalation of a small-scale spread to global
proportions.
4. The Parties shall commit to develop, as necessary, and implement coordinated policies and
measures for the safety and protection of workers who are essential for the normal functioning of critical
supply chains during pandemics, such as seafarers and cross-border transport workers, among others,
facilitating their transit and transfer, as well as ensuring their access to medical care, as appropriate.
5. The Parties shall collaborate, as appropriate, through multilateral and bilateral mechanisms to
minimize the negative impact of health workforce migration on health systems while respecting the
freedom of movement of health professionals, taking into account the applicable international codes and
standards.
A/INB/9/3 Rev.1

10
Article 8. Preparedness monitoring and functional reviews ? the provisions of this
Article were moved to Article 6 (retained for numbering purposes only)
Article 9. Research and development
1. The Parties shall cooperate to build, strengthen and sustain geographically diverse capacities and
institutions for research and development, particularly in developing countries, based on a shared
agenda, and shall promote research collaboration and access to research through open science
approaches for the rapid sharing of information and results, especially during pandemics.
2. To this end, the Parties shall promote, within the means and resources at their disposal:
(a) sustained investment in research and development for public health priorities;
(b) technology co-creation and joint venture initiatives, actively engaging the participation of
scientists and/or research centres from developing countries;
(c) capacity-building programmes, projects and partnerships, and substantial and sustained
support for all phases of research and development, including basic and applied research; and
(d) the participation of relevant stakeholders, consistent with applicable biosafety and
biosecurity obligations, laws, regulations and guidance, to accelerate innovative research and
development.
3. The Parties shall, in accordance with national circumstances and mindful of relevant international
standards and obligations, take steps to strengthen international coordination and collaboration to
support well-designed and well-implemented clinical trials, by developing, strengthening and sustaining
clinical trial capacities and research networks, at the national, regional and international levels, and
facilitating the rapid reporting and interpretation of data from such trials.
4. Each Party shall ensure that government-funded research and development agreements for the
development of pandemic-related health products include, as appropriate, provisions that promote
timely and equitable access to such products and shall publish the relevant terms. Such provisions may
include: (i) licensing and/or sublicensing, preferably on a non-exclusive basis; (ii) affordable pricing
policies; (iii) technology transfer on mutually agreed terms; (iv) publication of relevant information on
research inputs and outputs; and/or (v) adherence to product allocation frameworks adopted by WHO.
Article 10. Sustainable and geographically diversified production, and technology
transfer and know-how
1. The Parties commit to achieving more equitable geographical distribution and scaling up of the
global production of pandemic-related health products and increasing sustainable, timely, fair and
equitable access to such products, as well as reducing the potential gap between supply and demand
during pandemics, through the transfer of relevant technology and know-how on mutually agreed terms.
2. The Parties, in collaboration with WHO and other relevant organizations, shall:
(a) take measures to provide support for, maintain and/or strengthen, as appropriate, facilities
at national and regional levels, particularly in developing countries, and those that have conducted
disease burden studies relevant to pathogens with pandemic potential, with a view to promoting
A/INB/9/3 Rev.1

11
the sustainability of such investments, for the production or scaling up of production of relevant
pandemic-related health products;
(b) take measures, in accordance with national and/or domestic laws, as appropriate, and
regulations to identify and contract with manufacturers other than those referenced in
paragraph 2(a) of this Article, for scaling up the production of pandemic-related health products,
during pandemics, in cases where the production and supply capacity of the production facilities
does not meet demand;
(c) actively support, participate in and/or implement, as appropriate, relevant WHO
technology, skills and know-how transfer programmes to facilitate strategically and
geographically distributed production of pandemic-related health products; and
(d) promote and incentivize public and private sector investments and/or partnerships aimed at
creating or expanding manufacturing facilities or capacities for pandemic-related health products,
especially facilities with a regional operational scope that are based in developing countries.
Article 11. Transfer of technology and know-how for the production of
pandemic-related health products
1. Each Party shall, in order to enable the sufficient, sustainable and geographically diversified
production of pandemic-related health products, and taking into account its national circumstances:
(a) promote and otherwise facilitate or incentivize the transfer of technology and know-how
for pandemic-related health products, in particular for the benefit of developing countries and for
technologies that have received public funding for their development, through a variety of
measures such as licensing, on mutually agreed terms;
(b) publish the terms of its licenses for pandemic-related health technologies in a timely
manner and in accordance with applicable law, and shall encourage private rights holders to do
the same;
(c) encourage research and development institutes and manufacturers, in particular those
receiving significant public financing, to forgo or reduce, for a limited duration, royalties on the
use of their technology for the production of pandemic-related health products;
(d) promote the transfer of relevant technology and related know-how for pandemic-related
health products by private rights holders, on fair and most favourable terms, including on
concessional and preferential terms and in accordance with mutually agreed terms and conditions,
to established regional or global technology transfer hubs or other multilateral mechanisms or
networks, as well as the publication of the terms of such agreements;
(e) encourage the holders of relevant patents that received public funding and, where
appropriate, other holders of relevant patents for pandemic-related health products, to forgo
royalties or otherwise license any relevant patents at reasonable royalties to developing country
manufacturers for the use, during the pandemic, of their technology and know-how for the
production of pandemic-related health products; and
(f) encourage manufacturers within its jurisdiction to share as appropriate, during pandemics,
information that is relevant to the production of pandemic-related health products when the
A/INB/9/3 Rev.1

12
withholding of such information prevents or hinders the urgent manufacture of a pharmaceutical
product that is necessary to respond to the pandemic.
2. Each Party shall provide, within its capabilities and subject to available resources and applicable
law, support for capacity-building for the transfer of technology and know-how for pandemic-related
health products on mutually agreed terms, especially to local, subregional and/or regional manufacturers
based in developing countries.
3. Consider supporting, within the framework of relevant organizations, appropriate measures to
accelerate or scale up the manufacturing of pandemic-related health products, to the extent necessary to
increase the availability and adequacy of affordable pandemic-related health products during pandemics.
4. The Parties that are World Trade Organization (WTO) members reaffirm that they have the right
to use, to the full, the flexibilities in the TRIPS Agreement, including those reaffirmed in the Doha
Declaration on the TRIPS Agreement and Public Health of 2001, which provide flexibility to protect
public health in future pandemics, and shall fully respect the use of the TRIPS Agreement flexibilities
by WTO members.
5. The Parties shall, working through the Conference of the Parties, establish regional or global
technology and know-how transfer hubs, coordinated by WHO, to increase and geographically diversify
the transfer of technology and know-how for the production of pandemic-related health products by
manufacturers in developing countries.
Article 12. Access and benefit-sharing
1. A multilateral access and benefit-sharing system for pathogens with pandemic potential, the WHO
Pathogen Access and Benefit-Sharing System (PABS System), is hereby established to ensure the rapid,
systematic and timely sharing of PABS material and information for, inter alia, public health risk
assessment and, on an equal footing, timely, effective, predictable and equitable access to
pandemic-related health products and other benefits, both monetary and non-monetary, arising from
such sharing. The PABS System shall be coordinated and convened by WHO.
2. The PABS System shall have the following foundations:
(a) the commitment of Parties to share, on an equal footing, PABS material and information
and the benefits arising therefrom, considering these as equally important parts of the collective
action for global public health;
(b) its implementation in a manner to strengthen, expedite and not stifle research and
innovation;
(c) its implementation in a manner to ensure mutual complementarity with the Pandemic
Influenza Preparedness Framework;
(d) its implementation in accordance with applicable biosafety, biosecurity and data protection
standards;
(e) the development of a robust, inclusive, transparent, Member State-led and science-based
governance, review and accountability mechanism(s);
(f) not seeking to obtain intellectual property rights on PABS material and information; and
A/INB/9/3 Rev.1

13
(g) its implementation in a manner to be consistent with, and not to run counter to, the
objectives of the Convention on Biological Diversity and its Nagoya Protocol on Access to
Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization
with a view to providing legal certainty to PABS System providers and users, and with the aim
of the recognition of the PABS System as a specialized international access and benefit-sharing
instrument within the meaning of paragraph 4 of Article 4 of the Nagoya Protocol.
3. The PABS System shall have, at a minimum, the following components and elements:
(a) the rapid, systematic and timely sharing of PABS material and information and all relevant
information, in accordance with modalities, terms and conditions to be determined and agreed;
and
(b) the fair, equitable and timely sharing of benefits, both monetary and non-monetary, arising
from access to PABS material and information, in accordance with modalities, terms and
conditions to be determined and agreed, which shall include, at a minimum, the following:
(i) in the event of a pandemic, real-time access by WHO to 20% (10% as a donation
and 10% at affordable prices to WHO) of the production of safe, efficacious and effective
pandemic-related health products; and
(ii) annual monetary contributions from PABS System users shall be administered by
WHO, based on modalities, terms and conditions to be defined, as per paragraph 6 of this
Article; and
(c) a mechanism to ensure the fair and equitable allocation and distribution of the
pandemic-related health products stipulated in paragraph 3(b) of this Article shall be developed,
taking into account public health risks, needs and demand, as per paragraph 6 of this Article.
4. The PABS System will also have additional benefit-sharing options, which may include:
(a) voluntary non-monetary contributions, such as capacity-building activities, scientific and
research collaborations, non-exclusive licensing agreements, arrangements for the transfer of
technology and know-how of relevant diagnostics, therapeutics or vaccines in line with
Article 11, tiered-pricing or other cost-related arrangements, such as no loss/no profit loss
arrangements, for the purchase of pandemic-related health products during public health
emergencies of international concern or pandemics; and
(b) encouraging laboratories in the WHO-coordinated laboratory network to actively seek the
participation of scientists from developing countries in scientific projects associated with research
on PABS material and information.
5. Each Party that has manufacturing facilities that produce pandemic-related health products in its
jurisdiction shall take all necessary steps to facilitate the export of such products, in accordance with
timetables to be agreed between WHO and the relevant manufacturers.
6. The modalities, terms and conditions, and operational dimensions of the PABS System shall be
further defined in a legally binding instrument that will be operational no later than 31 May 2026.
A/INB/9/3 Rev.1

14
Article 13. Supply chain and logistics
1. The Global Supply Chain and Logistics Network (the Network) is hereby established to enhance
equitable, timely and affordable access to pandemic-related health products. The Network shall be
developed, coordinated and convened by WHO in partnership with the Parties and other relevant
international and regional stakeholders. The Parties shall prioritize sharing through the Global Supply
Chain and Logistics Network for equitable allocation based on public health risk and need over bilateral
donation agreements.
2. The Conference of the Parties shall, at its first meeting, define the structure and modalities of the
Network, which shall aim at ensuring the following:
(a) collaboration among the Parties and other relevant stakeholders during and between
pandemics;
(b) the functions of the Network are discharged by the organizations best placed to perform
them;
(c) consideration of the needs of developing countries and the needs of persons in vulnerable
situations, including those in fragile and humanitarian settings;
(d) the equitable allocation of pandemic-related health products; and
(e) accountability and transparency in the functioning and governance of the Network.
3. The Parties shall periodically review the operations of the Network, including the support
provided by Parties and other stakeholders during and between pandemics.
4. During a pandemic, emergency trade measures shall be targeted, proportionate, transparent and
temporary, and not create unnecessary barriers to trade or disruptions in supply chains of
pandemic-related health products.
5. During a pandemic, the rapid and unimpeded access of humanitarian relief personnel, their means
of transport, supplies and equipment and their access to pandemic-related health products shall be
facilitated in a manner consistent with relevant provisions of international law, including international
humanitarian law, and in respect of the principles of humanity, neutrality, impartiality and independence
for the provision of humanitarian assistance.
6. A multilateral system for managing vaccine and therapeutic-related compensation and liability
during pandemics shall be considered.
7. The WHO, as the convenor of the Network, shall report regularly to the Conference of the Parties
on all matters relevant to the implementation of this Article.
Article 13bis. National procurement and distribution
1. Each Party shall publish the relevant terms of its purchase agreements with manufacturers for
pandemic-related health products at the earliest reasonable opportunity, and shall exclude confidentiality
provisions that serve to limit such disclosure, in accordance with applicable laws, as appropriate.
Regional and global purchasing mechanisms shall also be encouraged to do the same.
A/INB/9/3 Rev.1

15
2. During a pandemic, each Party in a position to do so shall, within its available resources and
subject to applicable laws, set aside a portion of its total procurement of relevant diagnostics,
therapeutics or vaccines in a timely manner for use in countries facing challenges in meeting public
health needs and demand.
3. Each Party shall take appropriate measures to promote rational use and reduce the waste of
pandemic-related health products.
4. Each Party undertakes to avoid having national stockpiles of pandemic-related health products
that unnecessarily exceed the quantities anticipated to be needed for domestic pandemic preparedness
and response.
5. When sharing pandemic-related health products with countries, organizations or any mechanism
that is facilitated by the Network, such products will be unearmarked and accompanied by all appropriate
and relevant conditions, requirements and characteristics, as well as ancillary products, that are
necessary for their distribution, administration and dispensing.
6. Each Party shall endeavour to ensure that, in contracts for the supply or purchase of novel
pandemic vaccines, buyer/recipient indemnity clauses, if any, are exceptionally provided and are
time-bound.
Article 14. Regulatory strengthening
1. Each Party shall strengthen its national and, where appropriate, regional regulatory authority
responsible for the authorization and approval of pandemic-related health products, including through
technical assistance and cooperation with WHO, other Parties and relevant organizations, as and when
requested, with the aim of ensuring the quality, safety and efficacy of such products.
2. Each Party shall take steps to ensure that it has the legal, administrative and financial frameworks
in place to support emergency regulatory authorizations for the effective and timely approval of
pandemic-related health products during a pandemic, the monitoring of adverse events and the sharing
of regulatory dossiers through WHO, as appropriate.
3. Each Party shall, in accordance with relevant laws:
(a) encourage manufacturers of pandemic-related health products to generate and submit in a
timely manner the relevant regulatory data, contribute to the development of common technical
documents, and diligently pursue national regulatory authorizations and approvals and, as
appropriate, prequalification with WHO and WHO listed authorities; and
(b) publicly disclose information on national and, if applicable, regional processes for
authorizing or approving the use of pandemic-related health products, and adopt regulatory
reliance processes or other relevant regulatory pathways, as appropriate, for such pandemic-
related health products that may be activated during a pandemic to increase efficiency, and shall
update such information in a timely manner.
4. The Parties shall, as appropriate, monitor, regulate and strengthen rapid alert systems against
substandard and falsified pandemic-related health products.
5. The Parties shall align and, where possible, harmonize technical and regulatory requirements and
procedures, in accordance with applicable international standards, guidance and protocols, including
A/INB/9/3 Rev.1

16
those covering regulatory reliance and mutual recognition, and shall make publicly available relevant
information, data and assessments concerning the quality, safety and efficacy of pandemic-related health
products with other Parties.
Article 15. Compensation and liability management ? the provisions of this Article were
integrated into Articles 13 and 13bis (retained for numbering purposes only)
Article 16. International collaboration and cooperation ? the provisions of this Article
were integrated with Article 19 (retained for numbering purposes only)
Article 17. Whole-of-government and whole-of-society approaches
1. The Parties are encouraged to adopt whole-of-government and whole-of-society approaches at
national level, including to empower and enable community ownership of, and contribution to,
community readiness for and resilience to pandemic prevention, preparedness and response.
2. Each Party is urged to establish or strengthen, and maintain, a national multisectoral coordination
mechanism for pandemic prevention, preparedness and response.
3. Each Party shall, taking into account its national circumstances:
(a) promote the effective and meaningful engagement of communities and other relevant
stakeholders as part of a whole-of-society approach in planning, decision-making,
implementation, monitoring and evaluation, and shall also provide effective feedback
opportunities; and
(b) take appropriate measures to mitigate the socioeconomic impacts of pandemics and
strengthen national public health and social policies to facilitate a rapid, resilient response to
pandemics, especially for persons in vulnerable situations, including by mobilizing social capital
in communities for mutual support.
4. Each Party shall develop, in accordance with national context, comprehensive national pandemic
prevention, preparedness and response plans that address pre-, post- and interpandemic periods, in a
transparent manner that promotes collaboration with relevant stakeholders, including the private sector
and civil society, avoiding all forms of conflicts of interest.
5. The Parties shall promote and facilitate, in accordance with national and/or domestic law, as
appropriate, and policy, the development and implementation of education and community engagement
programmes on pandemic and public health emergencies, with the participation of all relevant
stakeholders, in a way that is accessible, including to persons in vulnerable situations.
Article 18. Communication and public awareness
1. The Parties shall strengthen science, public health and pandemic literacy in the population, as
well as access to transparent, accurate, science- and evidence-informed information on pandemics and
their causes, impacts and drivers, particularly through risk communication and effective
community-level engagement.
2. The Parties shall, as appropriate, conduct research to inform policies on factors that hinder or
strengthen adherence to public health and social measures in a pandemic and trust in science and public
health institutions, authorities and agencies.
A/INB/9/3 Rev.1

17
Article 19. International cooperation and support for implementation
1. The Parties shall cooperate, directly or through relevant international organizations, within the
means and resources at their disposal, to sustainably strengthen the pandemic prevention, preparedness
and response capacities of all Parties, particularly developing country Parties. Such cooperation shall
promote the transfer of technology on mutually agreed terms and the sharing of technical, scientific and
legal expertise, as well as financial assistance and support for capacity-strengthening for those Parties
that lack the means and resources to implement the provisions of this Agreement, and shall be facilitated
and provided by WHO, in collaboration with relevant organizations, as appropriate, upon the request of
the Party, to fulfil the obligations arising from this Agreement.
2. Particular consideration shall be given to the specific needs and special circumstances of
developing country Parties in order to enable them to implement the provisions of this Agreement.
3. The Parties shall collaborate and cooperate for pandemic prevention, preparedness and response
through strengthening and enhancing cooperation among relevant legal instruments and frameworks and
relevant global, regional, subregional and sectoral organizations and stakeholders, in the achievement
of the objectives of this Agreement, while closely coordinating support with that provided under the
International Health Regulations (2005).
Article 20. Sustainable financing
1. The Parties shall strengthen sustainable and predictable financing, in an inclusive and transparent
manner, for implementation of this Agreement and the International Health Regulations (2005).
2. In this regard, each Party, within the means and resources at its disposal, shall:
(a) maintain or increase, as necessary, domestic funding for pandemic prevention,
preparedness and response;
(b) mobilize additional financial resources to assist Parties, in particular developing country
Parties, in the implementation of the WHO Pandemic Agreement, including through grants and
concessional loans;
(c) explore, and as appropriate, promote, within relevant bilateral, regional and/or multilateral
funding mechanisms, innovative financing measures, including transparent financial
reprogramming plans for pandemic prevention, preparedness and response, especially for
developing country Parties experiencing fiscal constraints; and
(d) encourage governance and operating models of existing financing entities to minimize the
burden on countries, offer improved efficiency and coherence at scale, enhance transparency and
be responsive to the needs and national priorities of developing countries.
3. A Coordinating Financial Mechanism (the Mechanism) is hereby established to provide
sustainable financing support, strengthen and expand capacities for pandemic prevention, preparedness
and response, and to provide any surge response necessary for day zero, particularly in developing
country Parties. The Mechanism shall, inter alia:
(a) conduct relevant needs and gaps analyses to support strategic decision-making and develop
every five years a financial and implementation strategy for the Pandemic Agreement, and submit
it to the Conference of the Parties for its consideration;
A/INB/9/3 Rev.1

18
(b) promote harmonization, coherence and coordination for financing pandemic prevention,
preparedness and response and International Health Regulations (2005)-related capacities;
(c) identify all sources of financing that are available to serve the purposes of supporting the
implementation of this Agreement, and maintain a dashboard of such instruments and related
information and the funds allocated to countries from such instruments;
(d) establish, as necessary, following a mandate from the Conference of the Parties, working
arrangements with relevant identified financing instruments and entities to facilitate their support
of the financial and implementation strategy;
(e) provide advice and support, upon request, to Parties in identifying and applying for
financial resources for strengthening pandemic prevention, preparedness and response; and
(f) leverage voluntary monetary contributions for organizations and other entities supporting
pandemic prevention, preparedness and response, free from conflicts of interest, from relevant
stakeholders, in particular those active in sectors that benefit from international work to strengthen
pandemic prevention, preparedness and response.
4. The Mechanism shall function under the authority and guidance of the Conference of the Parties
and be accountable to it. The Conference of the Parties shall adopt terms of reference for the Mechanism
and modalities for its operationalization and governance, within 12 months after the entry into force of
the WHO Pandemic Agreement.
5. The Conference of the Parties shall periodically consider, as appropriate, the financial and
implementation strategy for the Pandemic Agreement referred to in paragraph 3(a) of this Article. The
Parties shall endeavour to align with it, as appropriate, when providing external financial support for the
strengthening of pandemic prevention, preparedness and response.
Chapter III. Institutional arrangements and final provisions
Article 21. Conference of the Parties
1. A Conference of the Parties is hereby established.
2. The Conference of the Parties shall regularly take stock of the implementation of the WHO
Pandemic Agreement and review its functioning every five years, and shall take the decisions necessary
to promote its effective implementation. To this end, it shall take actions, as appropriate, for the
achievement of the objective of the WHO Pandemic Agreement.
3. The first session of the Conference of the Parties shall be convened by the World Health
Organization not later than one year after the entry into force of the WHO Pandemic Agreement. The
Conference of the Parties will determine the venue and timing of subsequent regular sessions at its first
session.
4. Extraordinary sessions of the Conference of the Parties shall be held at such other times as may
be deemed necessary by the Conference of the Parties or at the written request of any Party, provided
that, within six months of the request being communicated in writing to the Parties by the Secretariat, it
is supported by at least one third of the Parties. Such extraordinary sessions may be called at the level
of heads of state or government.
A/INB/9/3 Rev.1

19
5. The Conference of the Parties shall, at its first session, adopt by consensus its rules of procedure
and its criteria for the participation of observers at its proceedings.
6. The Conference of the Parties shall by consensus adopt financial rules for itself, as well as
governing the funding of any subsidiary bodies it may establish and the functioning of the Secretariat.
At each ordinary session, it shall adopt a budget for the financial period until the next ordinary session.
7. The Conference of the Parties may establish subsidiary bodies, as it deems necessary, and
determine the terms and modalities of such bodies.
Article 22. Right to vote
1. Each Party to the WHO Pandemic Agreement shall have one vote, except as provided for in
paragraph 2 of this Article.
2. A regional economic integration organization that is Party to the WHO Pandemic Agreement, in
matters within its competence, shall exercise its right to vote with a number of votes equal to the number
of its Member States that are Parties to the WHO Pandemic Agreement. Such an organization shall not
exercise its right to vote if any of its Member States exercises its right to vote, and vice versa.
Article 23. Reports to the Conference of the Parties
1. Each Party shall report periodically to the Conference of the Parties, through the Secretariat, on
its implementation of the WHO Pandemic Agreement.
2. The frequency and format of the reports submitted by all Parties shall be determined by the
Conference of the Parties.
3. The Conference of the Parties shall adopt appropriate measures to assist Parties, upon request, in
meeting their obligations under this Article, with particular attention to the needs of developing country
Parties.
4. The reporting and exchange of information under the WHO Pandemic Agreement shall be subject
to national and/or domestic law, as appropriate, regarding confidentiality and privacy. The Parties shall
protect, as mutually agreed, any confidential information that is exchanged. The periodic reports
submitted by the Parties shall be made publicly available online by the Secretariat.
Article 24. Secretariat
1. Secretariat functions for the WHO Pandemic Agreement shall be provided by the
WHO Secretariat.
2. The Secretariat shall perform the functions specified by the WHO Pandemic Agreement, as
appropriate, and such other functions as may be determined by the Conference of the Parties or assigned
to it under the WHO Pandemic Agreement.
3. Nothing in the WHO Pandemic Agreement shall be interpreted as providing the WHO Secretariat,
including the WHO Director-General, any authority to direct, order, alter or otherwise prescribe the
national and/or domestic laws, as appropriate, or policies of any Party, or to mandate or otherwise
impose any requirements that Parties take specific actions, such as ban or accept travellers, impose
vaccination mandates or therapeutic or diagnostic measures or implement lockdowns.
A/INB/9/3 Rev.1

20
Article 25. Settlement of disputes
1. In the event of a dispute between two or more Parties concerning the interpretation or application
of the WHO Pandemic Agreement, the Parties concerned shall seek through diplomatic channels a
settlement of the dispute through negotiation or any other peaceful means of their own choice, including
good offices, mediation or conciliation. In case of failure to reach a solution by the methods mentioned
above, the Parties may continue to seek solutions to the dispute through joint consultations, including,
if they so agree, by resorting to ad hoc arbitration in accordance with the Permanent Court of Arbitration
Rules 2012 or successor rules. The Parties that have agreed to arbitration shall accept the arbitration
award as binding and final.
2. The provisions of this Article shall apply with respect to any protocol as between the Parties to
the protocol, unless otherwise provided therein.
Article 26. Relationship with other international agreements and instruments
1. The interpretation and application of the WHO Pandemic Agreement shall be guided by the
Charter of the United Nations and the Constitution of the World Health Organization.
2. The Parties recognize that the WHO Pandemic Agreement and the International Health
Regulations (2005) should be interpreted so as to be compatible and mutually reinforcing.
Article 27. Reservations
Reservations may be made to the WHO Pandemic Agreement unless incompatible with the object
and purpose of the WHO Pandemic Agreement.
Article 28. Declarations and statements
1. Article 27 does not preclude a State or regional economic integration organization, when signing,
ratifying, approving, accepting or acceding to the WHO Pandemic Agreement, from making
declarations or statements, however phrased or named, with a view, inter alia, to the harmonization of
its laws and regulations with the provisions of the WHO Pandemic Agreement, provided that such
declarations or statements do not purport to exclude or to modify the legal effect of the provisions of the
WHO Pandemic Agreement in their application to that State or regional economic integration
organization.
2. A declaration or statement made pursuant to this Article shall be circulated by the Depositary to
all Parties to the WHO Pandemic Agreement.
Article 29. Amendments
1. Any Party may propose amendments to the WHO Pandemic Agreement, including its annexes
and such amendments shall be considered by the Conference of the Parties.
2. The Conference of the Parties may adopt amendments to the WHO Pandemic Agreement. The
text of any proposed amendment to the WHO Pandemic Agreement shall be communicated to the Parties
by the Secretariat at least six months before the session at which it is proposed for adoption. The
Secretariat shall also communicate proposed amendments to the signatories of the WHO Pandemic
Agreement and, for information, to the Depositary.
A/INB/9/3 Rev.1

21
3. The Parties shall make every effort to adopt any proposed amendment to the WHO Pandemic
Agreement by consensus. If all efforts at consensus have been exhausted and no agreement has been
reached, the amendment may as a last resort be adopted by a three-quarters majority vote of the Parties
present and voting at the session. For the purposes of this Article, Parties present and voting means
Parties present and casting an affirmative or negative vote. Any adopted amendment shall be
communicated by the Secretariat to the Depositary, which shall circulate it to all Parties for acceptance.
4. Instruments of acceptance in respect of an amendment shall be deposited with the Depositary. An
amendment adopted in accordance with paragraph 3 of this Article shall enter into force, for those Parties
having accepted it, on the ninetieth day after the date of receipt by the Depositary of an instrument of
acceptance by at least two thirds of the Parties to the WHO Pandemic Agreement.
5. An amendment shall enter into force for any other Party on the ninetieth day after the date on
which that Party deposits with the Depositary its instrument of acceptance of the said amendment.
Article 30. Annexes
1. Annexes to the WHO Pandemic Agreement shall be proposed, adopted and shall enter into force
in accordance with the procedure set forth in Article 29.
2. Annexes to the WHO Pandemic Agreement shall form an integral part thereof and, unless
otherwise expressly provided, a reference to the WHO Pandemic Agreement constitutes at the same
time a reference to any annexes thereto.
Article 31. Protocols
1. Any Party may propose protocols to the WHO Pandemic Agreement. Such proposals shall be
considered by the Conference of the Parties.
2. The Conference of the Parties may adopt protocols to the WHO Pandemic Agreement. In adopting
these protocols, the decision-making terms of Article 29(3) shall apply, mutatis mutandis. In the event
that a protocol is proposed for adoption under Article 21 of the Constitution of the World Health
Organization, it shall further be presented to the World Health Assembly for consideration for adoption.
3. The text of any proposed protocol shall be communicated to the Parties by the Secretariat at least
six months before the session of the Conference of the Parties at which it is proposed for adoption.
4. States that are not Parties to the WHO Pandemic Agreement may be Parties to a protocol, provided
the protocol so provides.
5. Any protocol to the WHO Pandemic Agreement shall be binding only on the Parties to the
protocol in question. Only Parties to a protocol may take decisions on matters exclusively relating to the
protocol in question.
6. The requirements for entry into force of any protocol, and the procedure for the amendment of
any protocol, shall be established by that instrument.
Article 32. Withdrawal
1. At any time after two years from the date on which the WHO Pandemic Agreement has entered
into force for a Party, that Party may withdraw from the Agreement by giving written notification to the
Depositary.
A/INB/9/3 Rev.1

22
2. Any such withdrawal shall take effect upon expiry of one year from the date of receipt by the
Depositary of the notification of withdrawal, or on such later date as may be specified in the notification
of withdrawal.
3. A State shall not be discharged by reason of the withdrawal from the obligations which accrued
while it was a Party to the WHO Pandemic Agreement, nor shall the withdrawal affect any right,
obligation or legal situation of that State created through the execution of this Agreement prior to its
termination for that State.
4. Any Party that withdraws from the WHO Pandemic Agreement shall not be considered as having
also withdrawn from any protocol to which it is a Party, or from any related instrument, unless such a
Party formally withdraws from such other instruments and does so in accordance with the relevant terms,
if any, thereof.
Article 33. Signature
1. This Agreement shall be open for signature by all Members of the World Health Organization
and any States that are not Members of the World Health Organization but are Members or non-Member
Observer States of the United Nations, and by regional economic integration organizations.
2. This Agreement shall be open for signature at the World Health Organization headquarters in
Geneva, following its adoption by the World Health Assembly at its Seventy-seventh session, from
XX May 2024 to XX June 2024, and thereafter at United Nations Headquarters in New York, from
XX June 2024 to XX June 2025.
Article 34. Ratification, acceptance, approval, formal confirmation or accession
1. The WHO Pandemic Agreement shall be subject to ratification, acceptance, approval or accession
by all States and to formal confirmation or accession by regional economic integration organizations.
This Agreement and any protocol thereto shall be open for accession from the day after the date on
which the Agreement is closed for signature. Instruments of ratification, acceptance, approval, formal
confirmation or accession shall be deposited with the Depositary.
2. Any regional economic integration organization that becomes a Party to the WHO Pandemic
Agreement, without any of its Member States being a Party shall be bound by all the obligations under
the WHO Pandemic Agreement or any protocol thereto. In the case of those regional economic
integration organizations for which one or more of its Member States is a Party to the WHO Pandemic
Agreement, the regional economic integration organization and its Member States shall decide on their
respective responsibilities for the performance of their obligations under the Agreement. In such cases,
the regional economic integration organization and its Member States shall not be entitled to exercise
rights under the WHO Pandemic Agreement concurrently.
3. Regional economic integration organizations shall, in their instruments relating to formal
confirmation or in their instruments of accession, declare the extent of their competence with respect to
the matters governed by the WHO Pandemic Agreement and any protocol thereto. These organizations
shall also inform the Depositary, who shall in turn inform the Parties, of any substantial modification in
the extent of their competence.
A/INB/9/3 Rev.1

23
Article 35. Entry into force
1. This Agreement shall enter into force on the thirtieth day following the date of deposit of the
sixtieth instrument of ratification, acceptance, approval, formal confirmation or accession with the
Depositary.
2. For each State that ratifies, accepts or approves the WHO Pandemic Agreement or accedes thereto
after the conditions set forth in paragraph 1 of this Article for entry into force have been fulfilled, the
WHO Pandemic Agreement shall enter into force on the thirtieth day following the date of deposit of its
instrument of ratification, acceptance, approval or accession.
3. For each regional economic integration organization depositing an instrument of formal
confirmation or an instrument of accession after the conditions set forth in paragraph 1 of this Article
for entry into force have been fulfilled, the WHO Pandemic Agreement shall enter into force on the
thirtieth day following the date of deposit of its instrument of formal confirmation or of accession.
4. For the purposes of this Article, any instrument deposited by a regional economic integration
organization shall not be counted as additional to those deposited by Member States of that regional
economic integration organization.
Article 36. Depositary
The Secretary-General of the United Nations shall be the Depositary of the WHO Pandemic
Agreement and amendments thereto and of any protocols and annexes adopted in accordance with the
terms of the WHO Pandemic Agreement.
Article 37. Authentic texts
The original of the WHO Pandemic Agreement, of which the Arabic, Chinese, English, French,
Russian and Spanish texts are equally authentic, shall be deposited with the Secretary-General of the
United Nations.
= = =

https://www.who.int/teams/ihr/working-group-on-amendments-to-the-international-health-regulations-%282005%29

Eighth meeting of the Working Group on Amendments to the International Health Regulations (2005)
https://www.who.int/news-room/events/detail/2024/04/22/default-calendar/eighth-meeting-of-the-working-group-on-amendments-to-the-international-health-regulations-(2005)

International Health Regulations (2005) (IHR).

アジェンダ

proposed Bureau’s text.
https://apps.who.int/gb/wgihr/pdf_files/wgihr8/WGIHR8_Proposed_Bureau_text-en.pdf

和訳（機械翻訳）
https://123210.net/wordpress/tatenaoshi/wp-content/uploads/sites/3/2024/04/【パンデミック条約-IHR改定案】WGIHR8_Proposed_Bureau_text-en【和訳トライ】A.pdf

改定前のバージョン
https://123210.net/wordpress/tatenaoshi/wp-content/uploads/sites/3/2024/03/【パンデミック改正案-240314】A_inb9_3-en.cvx_.pdf

https://www-rumormillnews-com.translate.goog/cgi-bin/forum.cgi?read=239438&_x_tr_sl=auto&_x_tr_tl=ja&_x_tr_hl=ja&_x_tr_pto=wapp

(真剣に) 嘘をついているのは誰ですか: 国際保健規則条約の改正案を拒否してください

投稿者:ナマステ[電子メールを送信]
日付: 2024 年 4 月 22 日月曜日 07:21:00
www.rumormill.news/239438

遠くまで、そして広く共有

https://jamesroguski.substack.com/p/i-hold-these-truths-to-be-self-identify

国際保健規則の改正は、あなたが信じ込まされているようなものではありません。気を散らさないでください。集中力を維持しましょう。これらの修正案は悪質であり、拒否される必要があります。

ジェームス・ログスキー
4月22日

1年以上の秘密保持を経て、国際保健規則改正作業部会（WGIHR）はついに改正案の公式更新草案を発表した。

最新の提案は、対処すべき問題のいずれにもまったく対処できていません。

WHOがこれらの修正案をあたかも何らかの形で役立つかのように採択することを許可するのは、非常に見当違いです。

WHOの交渉が国家主権への攻撃であるという現在進行中の主張（以下にリストされているとおり）は、赤ニシンです。

「WHOの交渉は国家主権に対する攻撃ではない。

WHOの交渉は義務やロックダウンに関するものではない。

WHOの交渉は医師と患者の関係を掌握しようとするものではない。」

国際保健規則の改正案について知っていると思っていることはすべて忘れて、あたかも初めてその改正について学ぶかのように以下の文書を読むことを強くお勧めします。

https://apps.who.int/gb/wgihr/pdf_files/wgihr8/WGIHR8_Proposed_Bureau_text-en.pdf

https://genkimaru1.livedoor.blog/archives/2295124.html

さてはてメモ帳

プランデミック：ざっと振り返り用記事目録

さてはてメモ帳さんのサイトより
http://glassbead.blog.shinobi.jp/medical%20tyranny/documents%20listed
＜転載開始＞

動かぬ証拠！ロックフェラーの関係者がNWO計画を1969年に明らかにしていた　by Henry Makow Ph.D.
WHOは1974年から人々を永久的に不妊にするようなワクチンの開発に取り組んできました：COVID-19候補ワクチンの草案展望　WHO
邪悪な場所－ジョージア・ガイドストーン　By Vigilant　＋　薔薇の棘？

コロナウイルスパンデミックの時代にジョージアのガイドストーンに注目が向かっている　Niamh Harris

ジャック・アタリは1981年に詐欺デミックとジェノサイドを予言していた　By RM

ジャック・アタリ：NOW暴政の青写真　Ruby Eden　(Excerpts by henrymakow.com)

コロナウイルスは1981年の小説で不気味に予測されていた　By Vigilant Citizen

予測プログラミング？イスラエルの出版社は何年も前からCOVIDに似たパンデミックについて書いている　by Raul Diego　（1994）

ゲイリー・D・バーネット：Covid「ワクチン」バイオテロは数十年前から計画されていた　２

グレート・リセット高性能大型爆弾：9/11の2ヶ月後、慈善活動のカーネギーメダル賞で一緒にいるアンソニー・ファウチ、ジョージ・ソロス、ビル・ゲイツ・シニアとデビッド・ロックフェラー

証拠：Covidプランデミックは少なくとも9.11と同じ時期に計画されていた　Ethan Huff

注目に値するA・ファウチ博士　F. William Engdahl　（ゲイツ財団陰謀団の嘘つき博士）

Covidのバイオテロの痕跡は、CCPの協力者であるアントニー・ファウチとピーター・ダスザックにさかのぼる　Lance D Johnson

COVID-19コロナウイルス：2003年にCDCによって台本書きされたか？ デッドゾーン　ペスト　By Bill Sardi

映画『感染（コンテイジョン）』はコロナウイルス発生への青写真をどのように用意したか　Vigilant Citizen

COVID-19 封鎖：グローバルな人間実験　By　Vigilant Citizen　＋　Sylvia Brownie 『End of days』　(2008)

ロックフェラー財団は2010年に現在の「パンデミック」を脚本化していた　2020-10-24 17:27:00

「猫インフルエンザ」に関するシンプソンズのクリップは途方もなく予言的だった　By Vigilant Citizen 　（シークレット・メディアの陰謀団＆ワクチン）

いつまで踊ってるの？：2012年ロンドンオリンピック開会式で予告されたコロナウイルス

今、2012年のロンドンオリンピックの開会式を振り返るのは理にかなっている　newensign

グローバル・ロックダウンを想定した2013年のロックフェラー論文　John B

コロナウイルス・ワクチンにおけるパターン識別：DNA-オリガミの自己組織化効果　Mik Andersen　１、２、３

ファイザー、DNAナノロボットでイド・バチェレと提携　OUTRAGED HUMAN　１、２

ファイザーは、mRNA注射薬にDNAを永久に改変する「ナノボット」が含まれていることを認めている　Baxter Dmitry

グラフェン酸化物が秘伝のソースに？　パート２　Maryam Henein

グローバリストのクラウス・シュワブは、2016年に「グローバル・ヘルス・パス」と呼ばれるマイクロチップの埋め込みを呼びかけていた　Ethan Huff

カンシノ、ファイザー、シノファーム、アストラゼネカ、スプートニクのワクチンバイアルに酸化グラフェンとマイクロテクノロジーを確認　Orwell City

「SPARSパンデミック2025-2028」シミュレーションは、COVID-19に続く新たなコロナウイルスプランデミックの詳細を明らかにしている　HAF　（2017）

2017年の報告書では、Covidワクチンは有毒であるとされている　by Derrick Broze

2017年、ソロスは「2020年までに」愛国者を黙らせる計画を起草　 by Brabantian

「ポピー」－ パフォーマンス・アーティストがCovid 心理作戦を予言していた　CR

2018年、SARS2はUNCの冷凍庫にあった　Jim Haslam

パンデミックが目的を持って計画されたことの証明：数百万個のCOVID-19テストキットが 　2017年と2018年に販売された

パンデミックは計画されていたのか？　概要編　＋　世界保健機関はテロリストが運営している　ほか

COVID-19の起源を解明する：DEFUSE提案に迫る　Medriva Correspondents　＋　炎上するバイオ医薬品複合体　John leake

グローバル生物戦争：米国が運営するバイオラボは、ウクライナだけではない：アフリカやアジア太平洋地域にも配備されている　Ethan Huff

2019年にイタリアで記録されたCovidのアウトブレイクは、米国のバイオ研究所が引き起こしたのか？　Dr. Peter F. Mayer

病原体ゲーム絵巻　超速フラッシュバック　＋　数ヶ月を2週間に！迅速・簡便な新型コロナウイルス人工合成技術を開発　松浦善治教授

それは、ワクチンではありません。それは、あなたを病気にするように作られているのです。　Dr. David Martin

ファイザーの研究責任者：Covidワクチンは女性の不妊化である　Health & Money News
元ファイザーの科学者が武漢コロナウイルスに関する政府と大企業の欺瞞を警告　Ramon Tomey
実験的なcovidワクチンは、重要な臓器や血流に炎症性のスパイクタンパク質を溢れさせる生物兵器のデリバリーシステムである　Lance D Johnson
転移可能要素、胎盤の発達、卵子の活性化。細胞ストレスとAMPKがつなぐジャンプ遺伝子が人間の生命を生み出す　Jahahreeh Finley
シンシチン-１
爆弾：致命的な血栓の原因はcovidスパイクタンパク質であり、（意図的に）すべてのcovidワクチンに含まれていることを、ソーク研究所の科学論文が明らかにした　Mike Adams
Covidワクチンのスパイクタンパクは男性の生殖能力も攻撃する　Ethan Huff
人口削減警報: 衝撃的な新しい研究では、covidワクチンが「自然流産」によって5つの妊娠のうち4つを終了させることが明らかになった　Mike Adams

ファイザーのCOVID-19ワクチン1回分には2000億個以上のDNA断片が含まれており、この断片がヒトのDNAに取り込まれてがんを引き起こす可能性がある　Lance D Johnson

英国政府報告書によると、2029年までに英国のすべての空港が閉鎖され、気候詐欺の目標を達成するために牛肉と羊肉の食用が禁止される　The Exposé

ワクチンパスポートはパンデミックが始まる前から計画されていた　GreatGameIndia

シリーズ『ユートピア』がいかに2020年を不気味に予測したか　By Vigilant Citizen

2020年4月のロックフェラー財団の論文が米国の人口全体の検査と追跡を促している　By Makia Freeman

SARS-CoV-2/Wuhan-1/2020ウイルスは、米国疾病予防管理センター（CDC）からAndrew Pekosz博士に提供された

COVID発生前、ゲイツは製薬会社、CDC、メディア、中国、CIAとともにワクチン安全擁護者のソーシャルメディア検閲を計画していた　Robert F. Kennedy, Jr.

CDCは、covid-19スキャンダルの当初から中国共産党と連携していた　Lance D Johnson

WHOの真のアジェンダ：中国をモデルにした新世界秩序　By　Vigilant Citizen
コロナウイルスCOVID-19パンデミック：本当の危険は「アジェンダID2020」 By Peter Koenig
マイクロソフト、ビッグテック連合がロックフェラー出資のCOVIDパスポートを開発している　Steve Watson
ビル・ゲイツは、COVID-19ワクチンを受けた人間を特定するための「デジタル証明書」を要求　By Vigilant Citizen

そう、ビル・ゲイツが言っていた。これがその証拠だ　Robert F. Kennedy, Jr.

禁止されたドキュメンタリー – ビル・ゲイツがマイクロソフトからワクチンに切り替えた理由

ビル・ゲイツと他の大量殺戮サイコパス　helpfreetheearth ＋　エプスタインの友達 ダーショウィッツ、強制ワクチンへの支持を表明　＋　ロシア公共放送が驚愕の報道！！

マスク、社会的距離、仮想学習は、現実に、アメリカでの共産主義のインストールが目的である　S.D. Wells

プランデミックはグローバリストの策略－「最悪の事態はまだこれから来る」　by Steven Guinness

オーストラリア、親の同意なしに24,000人の子供に注射を行うための、スタジアム規模のcovid死の注射処理センターを立ち上げる　Ethan Huff

中国の反体制自由活動家、陳光誠が西側諸国に対して「我々の戸口にある」社会信用システムに警告を発した Claire Chretien

パンデミック・スリラー映画『ソングバード』は純粋な予測プログラミングになるだろう　By Vigilant Citizen　＋

クラウス・シュワブの「15分都市」構想が世界各地で進む　Redacted

非電離放射線を長時間浴びると、さまざまな健康被害が引き起こされる　Orwell City

ノルウェー人男性、陰謀に関する真実をフェイスブックに投稿し精神科に拘留される　Rhoda Wilson

オバマ夫妻製作の不穏な映画『世界を置き去りにする』に隠された象徴性　Vigilant Citizen　１、　２

NASAのブルービーム計画 － セルジュ・モナストが語る　Patricia Harrity　１

世界保健機関（WHO）が再び違法行為に踏み切ろうとしている　Senator Malcom Roberts

WHO保健政策の核心にある腐敗と欺瞞　Judy Wilyman PhD

COVID-19は、遺伝子兵器と生物学的実験を何波にもわたって住民に導入するための試験運用だった　Lance D Johnson

マコウ：すべてが台本通り　１

4年後、Fox NewsはCOVID起源の陰謀と隠蔽工作をすべて認めた　Lance D Johnson

日本から世界へのメッセージ－井上正康教授　Patricia Harrity

https://tyuuta1.com/wadai430/

「神の棒」によって破壊される34のサタニック遺跡のリストと写真

http://blog.livedoor.jp/sagittariun-shinjituwomiru/archives/40529069.html

KINGDOM

https://youtu.be/MA3iscoypcY?si=ntFHr599JdV3m0KV

ブログ
https://blg.hmasunaga.com/2016/10/24/post-179/

意見広告pdf(日刊ゲンダイ20161021)
https://blg.hmasunaga.com/hmadmeqdd/wp-content/uploads/2016/10/5e9cd6d8713b0a1ac6c650d2177c94a4.pdf

https://t.me/thefinalwakeupcallchannel/14767

完全な開示
ピーター・B・マイヤー著 – 4月20日。 2024年

目に見えない世界との関係は、通常の人間にとって善と悪の概念の下にあるアルコンと呼ばれる非人間的実体または精神寄生虫のせいで非常に複雑です。

重要なのは、イルミナティが私たちに信じ込ませているような、アヌンナキは私たちの創造者ではないということです。 彼らは私たちを奴隷として利用できるように私たちを操作しただけです。

ゼカリア・シッチン氏によると、アヌンナキは私たちの霊的側面の源では決してなく、純粋な愛のエネルギーから神によって創造されました。

目に見えないマスターは、不死の存在である知覚できない異次元の存在に属しており、秘密結社で慎重に選ばれた弟子に対する難解な教えの中でのみ宣言されています。

大衆文化とは対照的に、本当の隠れマスターはダークサイドのエイリアンではなく、慈悲深いエイリアンです。 慈悲深い存在たちは私たちの生活を支配したりコントロールしたりする必要はありません。 これは普遍的なオカルト法に違反します。

しかし、闇のエリートたちはこれらの法則を超えて立ち上がろうとしており、物質世界の守護者として行動しています。言い換えれば、彼らはアルコンであり、ほとんどのイスラム教徒と同様、オカルトエリートやオカルトエリートに雇われている、最も危険な精神内寄生虫です。 私たち国民を欺き、操作する諜報機関。

12 本の DNA 鎖のうち 10 本が切断されたことで、私たちの可能性は限られてしまいました。 一部のエイリアンは人類の遺伝子操作を助けましたが、アヌンナキはその後、12本のDNA鎖のうち10本を切断することで人類の遺伝学を破壊し、人類をエリートのために奴隷化しました。
https://cinemaphile.com/watch?v=qpcfZzx8xY0

これらの切断された鎖は、科学者によってジャンク DNA と呼ばれています。 実際、私たちは能力のほとんど、あるいはほとんどすべてを失い、独立して生き残ることができるより多くの奴隷を複製するためだけに、残った2本のDNA鎖に調整されています。 12 本の DNA 鎖がすべて復元されると、私たちは驚くべき能力を持つようになります。

これにより、大多数の人間は現在脳の 12 パーセントしか使用していないのに対し、私たちは再び脳を 100 パーセント使用できるようになります。

宇宙人は、私たちの創造的能力と多才な特質を備えた私たちの DNA 兵器を欲しがるでしょう。 彼らは私たちの創造性を羨望しており、それが私たちを不滅にします。 聖書にあるように、私たちは創造主に似せて造られています。 イエスが奇跡を行ったとき、こう言いました。

「これらのこともできます。」

アヌンナキが DNA の 12 鎖のうち 10 本を切断して私たちを奴隷にした時代以前、人類はこのようにして機能することができたのです。

カバールが作り出したあらゆるものは今、段階的に解体されつつあります。 最も重要なことは、彼らの世界的な不換紙幣経済は、ディープステートにその世界的支配を放棄させるために収縮しつつあるということです。

法定金融システムは、現地通貨、つまり、無価値になったり偽造されたりすることのない量子金融システムと統合された、金または銀を裏付けとしたソブリン通貨システムに置き換えられます。 これがGESARA後の世界の基礎です。
https://t.me/thefinalwakeupcallchannel

https://t.me/thefinalwakeupcallchannel/14781

創造的破壊
Peter B. Meyer 著 – 2024 年 4 月 21 日

事実;

• 「世界的な法定通貨の50年にわたる実験の結果として生じている混乱は、実質価値のある通貨への回帰を要求している。産油国が石油の代わりに金やそれに相当するものを要求する日が近いことを私たちは知るだろう。 (ペトロ)ドルかユーロは早ければ早いほど良いです。

• リチャード・デイは 1969 年の会合で、経済危機、大量失業、大量移民によって、古くから確立されたコミュニティが破壊されるだろうと語った。

ダムが決壊し始める
大衆の覚醒は世界が待ち望んでいたものです。 新型コロナウイルスのパンデミックが、ワクチン中毒によって自発的に国民を殺すためにでっち上げられたことに大衆が気づいたとき、水門が開きます。 人々は激怒し、あらゆる権威に対して復讐を求めます。 これは世界が待ち望んでいた瞬間です。

人々は欲しいものや市場から期待しているものを手に入れていません。 彼らは当然のことを手に入れています。 しかし、半世紀にもわたる失敗、失敗した投資、失敗した企業、デフォルトした個人の失敗がありました。 非常に多くの間違いを正さなければならない場合、それは不況と呼ばれ、現在起こっているように経済全体が悪化する場合、それは恐慌と呼ばれます。

市場が何らかの修正を加えようとするたびに、中央銀行家はより多くの紙幣を印刷し、より容易な信用をもたらしました。 何年も前に倒産するはずだった企業が、負債をさらに深め続けた。 住宅所有者も借金を負い続けた。

・「矯正の力は、それに先立つ欺瞞と同等であり、反対である。」

資本主義は、経済学者のヨーゼフ・シュンペーターが呼んだプロセスを通じて機能します。

• “創造的破壊”。

間違いを打ち破り、新しいイノベーションや新しいビジネスに道を譲ります。 いわゆる「創造的破壊」。

残念ながら、これは政府や多くの人々が望んでいることと矛盾しています。 人は間違いを犯すと、自分には責任がないと主張します。 「この危機を誰が予想できたでしょうか？」 彼らが聞く。 そして、「損失は他の誰かが支払ってください」と言います。

現在、中央銀行は「バブル時代に規制上の責任を誤って管理し、資金管理を誤った貸し手を保護するために、管理を誤った企業を救済した」。

全世界が知っているように、資本主義システムは今日米国にとっても世界にとっても機能しておらず、危機から危機へと、そのたびに前回よりもさらに深刻化しています。

中央銀行が「創造的破壊」のプロセスを遅らせ、注意をそらそうとすればするほど、回復に時間がかかり、最終的なコストは増大する。

・「うつ病の重症度は、それを阻止しようとする政府の取り組みと逆相関している。」

お金を印刷することは、既存の通貨、つまり人々が稼いで貯めたお金の価値を盗むこと、言い換えれば、古いお金の価値を盗むことです。

苦労して稼いだお金を貯めた人々は、購買力の一部を失っています。 彼らは確かに、お金を打ち切られることに決して同意しませんでした。 さらに悪いことに、彼らは自分たちのお金に何が起こっているのかまったく知りませんでした。 それで、誰が彼らに返済するのでしょうか？ 誰でもない。
https://t.me/thefinalwakeupcallchannel

https://t.me/rtnews/61195

チャド、ニジェールに続き米軍撤退要求

チャドがアジ・コッセイ空軍基地に駐留する米軍の撤退を要求したのは最近になって以来、アフリカはもはや米軍の駐留を容認していないようだ。

ニジェールは以前、米軍に国外退去を要請した。

https://youtu.be/H69YmuM-_KI?si=uN45qS6AzKKo8pSL

ニコニコ動画

https://www.nicovideo.jp/watch/sm41321420

https://x.com/N4er5BANKPkQFQe/status/1781563691730870536

Twitter(X)
接種が免除されて滑りました
https://x.com/k3bixG6s6gzLaYM/status/1780788952838127681

健発１２０９第２号
令和２年 12 月９日

（宛先）
都 道 府 県
各 保 健 所 設 置 市 衛生主管部（局）長 殿
特 別 区

(差出人)
厚 生 労 働 省 健 康 局 長
（ 公 印 省 略 ）

予防接種法及び検疫法の一部を改正する法律等の施行について
https://www.yoboseshu-rc.com/files/libs/994/202111241134302752.pdf

：
：
（４）一の（１）の予防接種を行う場合において、第８条又は第９条の規定は、新型
コロナウイルス感染症のまん延の状況並びに予防接種の有効性及び安全性に関
する情報その他の情報を踏まえ、政令で、当該規定ごとに対象者を指定して適用
しないこととすることができるものとすること。（附則第７条第４項関係）
：
：

おまけ、とても紛らわしい!

医政発１２０９第22号
産情発１２０９第２号
健 発１２０９第２号
生食発１２０９第７号
保 発１２０９第３号

令 和 ４ 年 12 月 ９ 日

（宛先）
都 道 府 県 知 事
各　保健所設置市長 殿
特 別 区 長

（差出人）
厚 生 労 働 省 医 政 局 長
厚生労働省大臣官房医薬産業振興・医療情報審議官
厚 生 労 働 省 健 康 局 長
厚生労働省大臣官房生活衛生・食品安全審議 官
厚 生 労 働 省 保 険 局 長
（ 公 印 省 略 ）

「感染症の予防及び感染症の患者に対する医療に関する法律等の一部を改正する法律」の
公布及び一部施行について（通知）
https://www.mhlw.go.jp/content/001022538.pdf

https://www.youtube.com/live/fsuORk9Z00E?si=mqqV-9E5CxDBAs7u

ニコニコ動画

https://www.nicovideo.jp/watch/so43657573?ref=search_key_video&playlist=eyJ0eXBlIjoic2VhcmNoIiwiY29udGV4dCI6eyJrZXl3b3JkIjoiXHUzMGQxXHUzMGYzXHUzMGM3XHUzMGRmXHUzMGMzXHUzMGFmXHU2NzYxXHU3ZDA0Iiwic29ydEtleSI6ImhvdCIsInNvcnRPcmRlciI6Im5vbmUiLCJwYWdlIjoxLCJwYWdlU2l6ZSI6MzJ9fQ&ss_pos=1&ss_id=37aa503c-153d-4590-8da7-fea82329320b

拡散希望動画ちゃん寝る さん
ニコニコ動画

https://www.nicovideo.jp/watch/sm43662111?ref=search_key_video&playlist=eyJ0eXBlIjoic2VhcmNoIiwiY29udGV4dCI6eyJrZXl3b3JkIjoiXHUzMGQxXHUzMGYzXHUzMGM3XHUzMGRmXHUzMGMzXHUzMGFmXHU2NzYxXHU3ZDA0Iiwic29ydEtleSI6ImhvdCIsInNvcnRPcmRlciI6Im5vbmUiLCJwYWdlIjoxLCJwYWdlU2l6ZSI6MzJ9fQ&ss_pos=11&ss_id=37aa503c-153d-4590-8da7-fea82329320b

パンデミック条約反対 池袋デモ行進 1/3
https://www.nicovideo.jp/watch/sm43662453

パンデミック条約反対 池袋デモ行進 2/3
https://www.nicovideo.jp/watch/sm43662495

パンデミック条約反対 池袋デモ行進 3/3
https://www.nicovideo.jp/watch/sm43662533

Telegram (https://t.me/neohistory1/870812)
sir Cheeze in TARTARIA JAPAN chat

https://t.me/neohistory1/870850

https://x.com/masami777777/status/1779087345784140096

https://www.epochtimes.jp/2024/04/217796.html

大紀元
【報道】パンデミック条約に反対するデモ、池袋に1万人超が集結
https://x.com/epochtimes_jp/status/1779178548521296379

https://newssharing.net/rfkjr-who

我那覇真子 Masako GanahaさんのX投稿動画
【生配信】パンデミック条約 国際保健規則改定反対デモ行進の様子
https://x.com/ganaha_masako/status/1779010769314824354

一旦途切れたのでこちらで再開してます。
https://x.com/MGOML_X2OA/status/1779052016448524683

https://youtu.be/7i0By6o7d1o?si=pEmeM1t8yjID6eCl

HOME
https://themillenniumreport.com/

TODAY’s POSTS
https://themillenniumreport.com/author/themillenniumreport/

G翻訳
HOME
https://themillenniumreport-com.translate.goog/?_x_tr_sl=auto&_x_tr_tl=ja&_x_tr_hl=ja&_x_tr_pto=wapp

TODAY’s POSTS（今日の投稿）
https://themillenniumreport-com.translate.goog/author/themillenniumreport/?_x_tr_sl=auto&_x_tr_tl=ja&_x_tr_hl=ja&_x_tr_pto=wapp

https://hotnews8.net/

マスコミが報じないニュース ＆ 気になる情報メモ
https://hotnews8.net/DSsokuho/

https://hotnews8.net/society/communism/deep-state-cultural-marxism

https://hotnews8.net/society/deep-state/color-revolution

https://x.com/kharaguchi/status/1775976241394544931

https://x.com/kharaguchi/status/1776326003142672864

米国が戦争にわざわざ介入しないことを明らかにすることは、イランがイスラエルに報復攻撃を行うことに関するハアードルを下げる。
ＤＳが戦争状態を作り出す常套手段にみえる。

https://x.com/kinoshitayakuhi/status/1766351236151046525

皆さんには納税を拒否する義務があります。

ニュルンベルク戦争犯罪法廷より
（日本語自動機械翻訳）
https://worldbeyondwar-org.translate.goog/crime-pay-tax/

衆議院インターネット審議中継

https://www.shugiintv.go.jp/jp/index.php?ex=VL&deli_id=55102&media_type=

https://m.youtube.com/watch?v=OA_9YCghM2U&noapp=1

https://jsn.or.jp/journal/document/56_8/1218-1224.pdf

https://aburano-hanashi.kuni-naka.com/4527

https://jglobal.jst.go.jp/detail?JGLOBAL_ID=202202214545047878

リチャードコシミズ氏、紅麹サプリに含まれるスタチンとワクチンの相互作用について言及

https://x.com/ric_koshimizu/status/1774250402265039251?s=20

https://www.healthy-pass.co.jp/blog/20210113-2/

食事由来のビタミンDや、皮膚において紫外線によって生成したビタミンDは、肝臓で25ヒドロキシビタミンD (25-OH-D3) になります。

続いて腎臓で活性型の1α-25ジヒドロキシビタミンD (1,25 (OH) 2D3) に代謝され、体内で利用されます。

ビタミンDの活性化にはマグネシウムが関わっており、マグネシウムが不足しているとビタミンDの活性化に影響が表れる可能性があります😣

https://muramo10.hatenablog.com/entry/2021/12/13/081945

7-デヒドロコレステロールは紫外線により皮膚でビタミンD3（コレカルシフェロール）となる。ビタミンＤ3は2つのヒドロキシル化（水酸基 －OH の導入）を経て活性化される。まず、ビタミンD3は肝臓で、25-ヒドロキシラーゼにより25(OH)D3（カルシジオール）となり、脂肪組織に貯蔵される。次に、腎臓、免疫細胞、肺上皮細胞や他の器官で1αヒドロキシラーゼにより活性型ステロイドホルモンである1,25(OH)2D3（カルシトリオール）となり、カルシウム代謝を調節するとともに自然免疫系と獲得免疫系を調節する。

ちなみに、ビタミンD3サプリはコレカルシフェロールであり、骨粗鬆症で整形外科医が処方するエディロールやアルファロールなどはカルシトリオールである。

https://muramo10.hatenablog.com/entry/2021/07/29/093106

https://alzhacker.com/role-of-magnesium-in-vitamin-d-activation-and-function/

ビタミンD3（コレカルシフェロール）は、太陽光を浴びると皮膚で生成される。したがって、ビタミンDは本物のビタミンではない。日光を十分に浴びている人は、サプリメントを摂取する必要はない。30,32,59,60 ビタミンDは、D3（動物由来）またはD2（非動物由来）のいずれも、重要な生物学的活性を持っていない。ビタミンDは、動物由来のD3でも、非動物由来のD2でも、生物学的活性を持たず、肝臓や腎臓で処理されて、生物学的活性を持つ1,25-ジヒドロキシビタミンD（1,25[OH]2D）になる必要があるとされている。この活性化プロセスは2つのステップで行われる。(1）肝臓でコレカルシフェロールが25-水酸化酵素によって25-ヒドロキシコレカルシフェロール（25[OH]2D）に水酸化され、（2）腎臓で25-ヒドロキシコレカルシフェロールが1α水酸化酵素によって1,25(OH)2Dに変換される1,2,32,38,61。肝の25-水酸化酵素と腎の1α-水酸化酵素の両方の酵素活性は、マグネシウム依存性のプロセスである。ビタミンDは、キャリアータンパク質に結合して血液中を輸送されるが、その主要なキャリアーはビタミンD結合タンパク質である。重要なことは、ビタミンD結合タンパク質の活性もまた、マグネシウム依存性のプロセスであるということである（図2）62,63。

図2　ビタミンDの合成におけるマグネシウムの役割

マグネシウムは、ビタミンDの合成と活性化に不可欠な補酵素

柏病院　　ビタミンDの基礎知識（がんとの関連）第2版

https://www.jikei.ac.jp/hospital/kashiwa/sinryo/40_02w7.html

25（OH）D（ビタミンD）

ビタミンD3の体内代謝
1.　ビタミンＤ3は人の皮膚で作られ、体中を循環する。
2.　7-デヒドロコレステロール（7-dehydrocholesterol）はビタミンD3の前駆体（プロビタミンD3）である。
3.　アセチル CoA（アセチルコエンザイムＡ：アセチル補酵素A）から7-デヒドロコレステロールができる。7-デヒドロコレステロールは還元されるとコレステロールになり、ステロイドホルモンになる。
4.
5.

動物
7-デヒドロコレステロール　⇒　紫外線と体温　⇒　ビタミンD3
（ビタミンD3の前駆体）　　　　　　　　　　　　　(コレカルシフェロール)
（プロビタミンD3）

新型コロナワクチンの接種状況を可視化する目的で、ダッシュボードを提供しています。

イベルメクチンの飲み方

https://www.nicovideo.jp/watch/sm40895382

コロナ臨床患者：　保険が効く（医療機関が国費請求ができる）
コロナ後遺症患者：　保険が効かない（薬事法に引っかかる＝国が認めていない）、自己責任で服用する必要あり
コロナワクチン後遺症患者：　保険が効かない（薬事法に引っかかる＝国が認めていない）、自己責任で服用する必要あり

#193_ワクチン後遺症の現実④～なぜ効くのか？ どう効くのか？ イベルメクチン服用者の証言　長尾チャンネル
https://www.nicovideo.jp/watch/sm41576777

https://youtu.be/uNo72B2Cdpg?si=9rlrg7VctHBMA_Fm

【本日の記者会見】キーワードは「ビタミンD」【河北新報 武田記者 とりあえずお疲れ様でした。】

https://youtu.be/Si7zZ4cPcUk?si=GqmjCvBJUUFTN-6v

平穏なときでも、パンデミックの予防という理由（口実）があれば、締約国に強制できる仕組み作りのようだ。 「One Healthアプローチ」聞こえはいいが、恐ろしい専制主義 Intergovernmental Negotiating Body 18-28 March 2024

https://apps.who.int/gb/inb/e/e_inb-9.html

A/INB/9/1
Provisional agenda

A/INB/9/2
Draft programme of work

A/INB/9/3
Revised draft of the negotiating text of the WHO Pandemic Agreement

https://www.nicovideo.jp/watch/so43534167

https://www.nicovideo.jp/watch/sm43523128

https://ch.nicovideo.jp/live-tekijuku